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Abstract 
 
In vitro investigation of the ubiquitination and degradation of p53 by Murine 
Double Minute 2 (MDM2) and Retinoblastoma Binding Protein 6 (RBBP6) 
 
L. S. Jooste, MSc (Biotechnology) thesis, Department of Biotechnology, Faculty of 
Natural Sciences, University of the Western Cape. 
 
p53 is one of the most important tumour suppressor proteins in the body which 
protects the cell against the tumourigenic effects of DNA damage by initiating 
processes such as apoptosis, senescence and cell cycle arrest. Regulation of p53 
is key — so that the abovementioned processes are not initiated inappropriately. 
The principle negative regulator of p53 is Murine Double Minute 2 (MDM2), a 
RING finger-containing protein which catalyses the attachment of lysine48-linked 
poly-ubiquitin chains, targeting it for degradation by the 26S proteasome. It has 
been found to work in conjunction with the MDM2 homologue MDMX. 
 
Retinoblastoma Binding Protein 6 (RBBP6) is a RING finger-containing protein 
known to play a role in mRNA 3’-end processing, as well as interacting with p53 
and another crucial tumour suppressor, pRb.  It has previously been shown to 
cooperate with MDM2 in the ubiquitination and degradation of p53 in vivo and acts 
as a scaffold.  
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The objectives of this project are to investigate the proposed role of RBBP6 in the 
MDM2-catalysed ubiquitination of p53 using a fully in vitro ubiquitination system. 
Due to the difficulty of expressing full length RBBP6 in bacteria, a shortened 
version, dubbed “R3” was used which includes the RING finger domain but 
excludes the domain identified in earlier studies as the p53-binding domain. 
Proteins required to set up the fully in vitro p53 ubiquitination assays – including 
E1 and E2 enzymes, MDM2, R3, p53 and ubiquitin - were all successfully 
expressed in bacteria. The active 26S proteasome was successfully purified out of 
human cell lysates using antibodies targeting the α2-subunit. 
 
Cloning, expression and purification results showed that p53, MDM2 and R3 were 
not very stable proteins to work with — with degradation being initiated almost 
immediately after expression and purification which progressed during the 
downstream processing of the proteins. Although levels of intact protein were not 
always high, they were sufficient for in vitro assays.  
 
MDM2 and GST-R3 were both capable of poly-ubiquitinating p53 independently in 
“partially in vitro” assays using human cell lysate. The fully in vitro ubiquitination of 
p53 using MDM2 and R3 was established based on the well-known MDM2/MDMX 
system. When acting together R3 and MDM2 was shown to produce poly-
ubiquitination which is lysine-48 linked and recognised by the 26S proteasome 
leading to degradation. When the proteasome inhibitor MG132 was added, the 
poly-ubiquitinated p53 was rescued from degradation. R3 was also shown to 
successfully poly-ubiquitinate p53 independently of MDM2 and also interact with 
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p53 in vitro. These results suggest R3 to be of the same order of importance as 
that of MDM2 — which is known to be the most important regulator of p53. It 
would also rule out the proposed model of RBBP6 functioning as a scaffold as it is 
able to poly-ubiquitinate p53 independent of MDM2.  
 
These results allow us to better understand the mechanism in which p53 is down-
regulated by E3s. 
 
Keywords: cancer, p53, tumour suppressor, ubiquitination, degradation, MDM2, 
RBBP6, R3, in vitro, protein 
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CHAPTER 1 
Literature Review 
 
1.1. Introduction 
The importance of functional p53 in suppression of human cancer has been 
demonstrated in numerous studies since its first identification during the 1970s. 
Up to 2013 it was the subject of more than 65 000 research papers (Hoe et al., 
2014) and has been honoured with titles as grand as “Guardian of the genome” 
(Efeyan & Serrano, 2007), “Cellular Gatekeeper” (Levine, A, 1997), “Policeman 
of Oncogenes” (Efeyan & Serrano, 2007) and “Death Star” (Vousden, K, 2000), 
amongst others. Functional loss of p53 can be due to mutation of the gene, 
denoted TP53, itself or to inactivation of the p53 signal transduction pathway. 
The TP53 gene has been found to be mutated in 30-50% of frequently-
occurring human cancers (Weinberg, R. 2007). Gain-of-function and dominant 
negative mutants of p53 have long been recognised as significant causes of 
tumourigenicity; a recent study has shown that mutant p53 is the main driver of 
breast cancer, prompting the authors to give it the less complimentary title of 
“Rebel Angel” (Walerych et al., 2012). The rare Li-Fraumeni syndrome is an 
autosomal dominant hereditary disorder in which the patient suffers early onset 
of several types of cancer, all caused by a mutant p53 loss-of-function allele 
(Hoe et al., 2014). 
 
However in many cases the p53 gene is not mutated, but p53 is nevertheless 
inactivated due to over-expression of negative regulators such as the human 
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orthologue of Murine Double Minute 2 (MDM2), also called HDM2, or its co-
regulator MDMX (Lee & Gu, 2010; Lee & Moore, 2014; Weinberg. R, 2007). (In 
the remainder of this thesis the term MDM2 will be used rather than HDM2, 
which is common practice in the literature). 
 
The primary function of p53 is as a transcription factor, transducing expression 
of genes initiating cell cycle arrest, DNA repair and apoptosis, among others. 
Since initiation of apoptosis in the wrong context can be catastrophic for an 
organism, p53 levels are kept low through the actions of E3 ubiquitin ligases, 
also known as E3s, catalysing the attachment of chains of ubiquitin moieties 
which serve to recruit p53 to the 26S proteasome, where it is degraded. The 
first and still the best characterised of these p53 targeting E3s is MDM2. 
Genotoxic stresses such as DNA damage catalyse the activation of kinases 
which phosphorylate the N-terminus of p53, abolishing ubiquitination by MDM2 
and causing p53 levels to rise (Brown et al., 2009, Lai et al., 2001). 
 
MDM2 is only one of a number of E3s known to target p53 in this manner 
(Honda et al., 1997; Schloush et al., 2011; Lee et al., 2012); and a full 
understanding of more of these E3s and their modes of action is therefore 
critical to ongoing efforts to design inhibitors to re-activate p53 by rescuing it 
from degradation (Lee et al., 2012). A hallmark of many E3s is the presence of 
a RING finger domain, whose function is to bind to the ubiquitin conjugating 
enzyme, also known as an E2. A 2007 study by Li and co-workers showed that 
Retinoblastoma Binding Protein 6, a RING finger-containing protein known to be 
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associated with mRNA 3’-end processing (RBBP6), may play such a role, either 
by directly ubiquitinating p53 or by assisting MDM2 to do so. The study was 
carried out in mice, and showed that knock-out of the RBBP6 gene led to 
embryonic death due to overexpression of p53 and widespread ectopic 
apoptosis. The study also demonstrated direct interaction between the MDM2 
and RBBP6 proteins (Li et al., 2007). The study concluded that RBBP6 
functions by activating the ubiquitination activity of MDM2 rather than having 
activity of its own. The aim of this thesis is to set up a fully in vitro ubiquitination 
assay to investigate the role of RBBP6 in ubiquitination of p53. The questions of 
particular interest will be (i) whether RBBP6 has E3 ligase activity of its own for 
p53 or acts only by enhancing the activity of MDM2 and (ii) whether the putative 
ubiquitination produced by RBBP6 leads to proteasomal degradation in vitro. 
 
1.2. The Ubiquitin Proteasome System  
The Ubiquitin Proteasome System (UPS) is a highly regulated system for rapid 
and efficient removal of specific proteins from the cell. Through the action of a 
number of dedicated enzymes, target proteins are tagged with polymers of 
ubiquitin moieties which act as recognition motifs for the 26S proteasome 
complex, causing them to be fed into the proteasome and digested into small 
peptides for re-use by the cell. The enzymes in question are the ubiquitin 
activating enzyme, also known as E1, ubiquitin conjugating enzymes, also 
known as E2s and ubiquitin-ligating enzymes, also known as E3s. In addition, 
certain ubiquitination systems require the use of an ubiquitin chain extension 
factor, also known as an E4 (Pant & Loranzo, 2014; Koegl et al., 1999). 
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Ubiquitin is an 8.5 kDa protein containing 76 amino acids, which is highly 
conserved across all eukaryotes but not present in either bacteria or Archaea 
(Sorokin et al., 2009). It contains a di-glycine motif at positions 76, which plays 
a crucial role in its conjugation to side-chain amino groups of lysine residues on 
target proteins, a process known as ubiquitination or mono-ubiquitination. 
Ubiquitin itself contains 7 lysine residues, at positions 6, 11, 27, 29, 33, 48 and 
63 respectively, which can form the attachment points for additional ubiquitin 
moieties, leading to the assembly of poly-ubiquitin chains. Typically, linkage is 
through only one of the internal lysines, giving rise to the concept of lysine48-
linked poly-ubiquitin chains, lysine63-linked chains and so on. Ubiquitination 
has been reported to give rise to a number of different results in addition to 
signalling degradation in the proteasome, including endocytosis of receptors 
and sorting into specific cellular compartments (Woelk et al., 2007). 
Ubiquitination is a reversible reaction; a number of iso-peptidases, known as 
de-ubiquitination enzymes, or DUBs, are present in cells which regulate the 
level of ubiquitination as well as removing ubiquitin tags from proteins for re-
cycling before they are degraded in the proteasome (Woelk et al., 2007). The 
ubiquitin proteasome system (UPS) is illustrated schematically in the Figure 1.1. 
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Figure 1.1. The ubiquitin proteasome system as depicted in Datuma & Lindsten (2010). 
Ubiquitin (Ub) is indicated in red and the substrate in grey. The ubiquitin activating enzyme (E1) 
is depicted in yellow, the ubiquitin conjugating enzyme (E2) in green and the ubiquitin-ligating 
enzyme (E3) in blue.  
 
 
In the first step, the E1 activates ubiquitin by hydrolysing ATP to ADP and using 
the liberated energy to create a high-energy thioester bond between the C-
terminus of ubiquitin and the side-chain SH group of the catalytic cysteine of the 
E1. In the second step ubiquitin is transferred from the E1 to the E2, where it 
again forms a thioester bond with the side-chain SH group of the catalytic 
cysteine of the E2. In the third step the ubiquitin-conjugated E2 is recruited to 
the substrate by the E3, where it is transferred to the side-chain amino group of 
a lysine on the substrate. The C-terminal carboxyl of ubiquitin forms a bond with 
the lysine amino group which is chemically identical to the peptide bonds found 
 
 
 
 
6 
 
on the backbone of peptides; however to distinguish them from backbone 
peptide bonds they are referred to as isopeptide bonds, which means “peptide-
like” (Metzger et al., 2014).  
 
The role of the E3 is to recognise and recruit the substrate to the ubiquitin-
conjugated E2, and hence it must contain a substrate binding domain as well as 
an E2-binding domain. E3s are therefore specific for one or a small number of 
substrates, and hence there must be approximately the same number of them 
as there are substrates requiring to be modified. In humans the number of E3s 
is more than 600. The E1, in contrast, needs to recognise only ubiquitin and the 
E2 and there are consequently fewer of them; in humans there are two – Uba 6 
and Ube1. The E2 needs to recognise the small number of E1s and a subset of 
the large number of E3s, and we may therefore expect there to be an 
intermediate number of them; in humans there are approximately 35 (van Wijk 
& Timmers, 2010; Metzger et al., 2014) 
 
The role of E2-binding domain is played by one of two different domains: the 
HECT (Homologous to E6-AP Carboxy Terminus) domain or the RING (Really 
Interesting New Gene) domain (Woelk et al., 2007; Windheim et al., 2008; 
Metzerger et al., 2014). HECT-type E3s transfer the ubiquitin from the E2 to the 
substrate via a catalytic cysteine on the HECT domain and hence becomes 
covalently attached to ubiquitin during the reaction. An important consequence 
of this mechanism is that the substrate and the E2 do not have to interact 
simultaneously with the E3. RING-type E3s, on the other hand, act purely as 
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adaptor molecules, binding the substrate and E2 simultaneously in order to 
facilitate transfer of the ubiquitin from the E2 to the substrate (Metzerger et al., 
2014).  
 
RING fingers are small 70-residue domains that coordinate a pair of Zn2+ ions in 
a cross-braced arrangement. U-boxes adopt essentially the same structure as 
RING fingers, but manage to do so without requiring the assistance of any 
bound zinc ions. The similarity of the structures of U-boxes and RING has 
raised the question of whether U-box-containing E3s are specific for any 
particular type of substrate or biological outcome. Soon after their first 
identification U-boxes were proposed to be specific to ubiquitin chain extension 
factors (E4s), which means that they are capable of extending existing ubiquitin 
chains but not adding the first one to the substrate. However a number of U-
box-containing proteins have since been shown to be able to catalyse ubiquitin 
of substrate molecules without the aid of other E3s (Kappo et al., 2011). Some, 
such as CHIP (C-terminus of Hsp70-associated protein), are known to 
associate with chaperones such as Hsp70, which has led to the current 
hypothesis that they are specific for chaperone-mediated degradation of 
misfolded proteins (Metzerger et al., 2014; Kappo et al., 2011). 
 
A distinction is drawn in the literature between “poly-ubiquitination”, “mono-
ubiquitination” and “multiple mono-ubiquitination”. Mono-ubiquitination, in which 
a single ubiquitin moiety is attached to the substrate, has been linked with non-
proteolytic processes such as endocytosis, DNA repair, nuclear export, 
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endosomal sorting, cytoplasmic translocation and histone regulation as shown 
in Figure 1.2 (Brooks et al., 2004, Woelk et al., 2007). The attachment of a 
single ubiquitin to more than one lysine residue on the protein is called multiple 
mono-ubiquitination, and sometimes “multi-ubiquitination”. Multiple mono-
ubiquitination may represent the signal for degradation of the protein by 
endocytosis in the lysosomes of the cell (Sorokin et al., 2009). Poly-
ubiquitination refers to the attachment of four or more ubiquitin moieties to a 
single lysine residue on a protein (Windheim et al., 2008), and involves internal 
isopeptide bonds between the C-terminus of each ubiquitin moiety and the side-
chain amino group of one of the seven lysines present on the next ubiquitin. 
The use of different internal lysines gives rise to differently-shaped chains, 
which is expected to account for the differing specificities of particular linkages. 
For example, a lysine48-linked chain is expected to bind specifically to part of 
the 19S cap of the proteasome in order to be degraded (Ciehanover & Stanhill, 
2014). Shi and co-workers (Shi et al., 2009) showed that multiple mono-
ubiquitination results in export of p53 from the nucleus, leading to poly-
ubiquitination and degraded in the cytoplasm. 
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Figure 1.2 The various fates of the different ubiquitin chains on a substrate. Lysine48-
linked chains are associated with degradation in the 26S proteasome. Adapted from Woelk et 
al., 2007.  
 
The 26S proteasome mediates degradation of lysine48 linked poly-ubiquitinated 
proteins. It is made up of a two parts: the 19S regulatory particle and the 20S 
core particle. The 20S core particle is a barrel-shaped structure made up of 14 
α- and 14 β-subunits, arranged in 4 rings of 7 subunits in a α7β7β7α7 
configuration and contains all the proteolytic activity. The masses of the α- and 
β-subunits are between 21 and 31 kDa each. The 19S regulatory particle is 
made up of 19 subunits, which include six related ATP-ase subunits and four 
non-ATPase subunits and the lid which contains nine non-ATPases subunits, 
which is responsible for recognising lysine48-lnked adducts, unfolding the 
 
 
 
 
10 
 
conjugated protein and feeding it into the 20S barrel (Hayter et al., 2005, Kao et 
al., 2012). 
 
Once a protein has been recognised for degradation by the 26S proteasome, it 
undergoes de-ubiquitination. De-ubiquitination is the removal of ubiquitin 
molecules from a ubiquitinated protein to restore it to its original state as 
depicted in Figure 1.1. For example the de-ubiquitinating protein HAUSP is able 
to restore ubiquitinated p53 to its unmodified form through the removal of the 
ubiquitin molecule from the protein. It is also able to de-ubiquitinate MDM2 and 
MDMX. Regulation of this de-ubiquitination process is still not well understood, 
but has important implications in stabilising p53 (Brooks & Gu, 2011).  
 
Methods for investigation of ubiquitination 
SDS-PAGE and Western blot 
The standard method of investigating ubiquitination involves separation on 
SDS-PAGE followed by a Western blot using an antibody targetting either the 
substrate or ubiquitin. A common method involves the use of HA-tagged 
ubiquitin, facilitating detection with anti-HA antibodies. However, difficulties can 
arise when probing for ubiquitin since both the E2 and the E3 may become 
ubiquitinated in addition to the substrate. Immunoprecipitation of the substrate 
prior to detection can be used to overcome this problem (Wu et al., 2011; Shi et 
al., 2009). 
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Another issue is the difficulty, using the SDS-PAGE method, of distinguishing 
between poly-ubiquitination at single substrate lysines and mono-ubiquitination 
at different substrate lysines, since both would lead to ladders of higher 
molecular weight species. In the present context, p53 contains 7 lysines on its 
C-terminus alone, and therefore mono-ubiquitination of each lysine would result 
in the protein with an effective molecular weight of at least 110 kDa. In the 
literature, the presence of bands under 140 kDa has been taken as evidence of 
multiple mono-ubiquitination, and bands above 140 kDa as evidence of poly-
ubiquitination (Wang et al., 2011). 
 
An alternative method of distinguishing between mono- and poly-ubiquitination 
is through the use of antibodies which bind specifically to poly-ubiquitin chains. 
These antibodies also have the capacity to distinguish between the different 
linkages. For example Newton and co-workers have developed antibodies 
which specifically detect K-48 and K-63 poly-ubiquitin chains (Newton et al., 
2008).  
 
Investigation of poly-ubiquitination in vivo or in cell lysates is further complicated 
by the action of de-ubiquitinating enzymes (DUBs), which remove ubiquitin 
moieties through hydrolysis of the isopeptide bond. A number of chemical 
inhibitors, including cysteine protease inhibitors such as iodoacetamide (IAA) 
and N-ethylmaleimide (NEM) have been used in order to overcome this problem 
(Hjerpe et al., 2009). However they have been found to be only partially 
effective due to their non-specificity. They were also not able to function for 
 
 
 
 
12 
 
extended periods of time in aqueous solutions, they only managed to partially 
inhibit ubiquitin proteases and they also caused aberrant covalent modifications 
which rendered them effectively useless in the study of poly-ubiquitination 
(Wilson et al., 2012; Hjerpe et al., 2009). 
 
In an attempt to improve the detection of poly-ubiquitination, Tandem Ubiquitin 
Binding Entities (TUBEs) were designed to bind to and protect poly-
ubiquitinated substrates from the action of DUBs and degradation by the 
proteasome. TUBEs are synthetic proteins comprising of four ubiquitin-
associated (UBA) domains linked in tandem (Hjerpe et al., 2009) and are 
available commercially from LifeSensors (Pennsylvania, USA). Different TUBEs 
are available that bind lysine48-linked and lysine63-linked chains respectively. 
An alternative to TUBEs is MultiDsk, which is a polymer of five repeats of the 
ubiquitin-associated domain from the yeast Dsk2 protein (Wilson et al., 2011). 
MultiDsk has been shown to protect poly-ubiquitinated proteins from the action 
of the DUBs and has been used as a mechanism to precipitate poly-
ubiquitinated proteins or to enrich for poly-ubiquitinated proteins. Unlike TUBEs, 
MultiDsk has been reported to bind equally to K48-and K63-linked poly-ubiquitin 
chains (Hjerpe et al., 2009; Wilson et al, 2012). 
 
Mass spectrometry  
During ubiquitination the carboxyl group of the glycine at the C-terminus of the 
ubiquitin molecule forms an isopeptide bond with the ε-amino group of a lysine 
residue on the substrate.  Ubiquitination of target proteins can be detected by 
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mass spectrometry using the tryptic digest method. Following separation on 
SDS-PAGE, potential ubiquitinated protein species are excised from the gel and 
subjected to in-gel tryptic digest and the resulting peptide fragments analysed 
by mass spectrometry. The sequence of ubiquitin ends -Arg-Gly-Gly, so tryptic 
digest following the Arg (trypsin cuts immediately after positively-charged 
residues) will leave di-glycine adducts, with a mass of 114.042 Da) attached to 
lysine residues on the substrates, as shown in Figure 1.3 (A). The dipeptide 
adds a mass of 114.042 Da onto the affected lysine residue of the protein which 
can be identified by matching fragment masses against the protein database, 
allowing for the addition of 114.042 Da per lysine residues (Figure 1.3 (A)). 
Mass spectrometry has the advantage that it can identify the precise site of 
modification (Xu & Peng., 2007; Xu et al., 2010). Antibodies specifically 
recognising Lys-iso-Gly-Gly adducts are available commercially which can be 
used to enrich peptides prior to the mass spectrometry step (Figure 1.3 (B)).  
 
 
1.3. Retinoblastoma Binding Protein 6 
Retinoblastoma Binding Protein 6 (RBBP6) is a 200 kDa protein which has 
been shown to interact directly with both the tumour suppressor proteins p53 
and pRb. It is known to form part of the mRNA 3’-end processing complex in 
humans (Shi et al., 2009) and to play a role in 3’-end processing in humans (Di 
Giammartino et al., 2014) and in yeast (Lee & Moore, 2014). Studies show that 
it is essential for viability in a number of organisms, including yeast (Vo et al., 
2001), the worm C. elegans (Huang et al., 2013), the fruit fly D. melanogaster 
(Mather et al., 2005) and mouse (Li et al., 2007). 
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Figure 1.3. Using mass spectrometry to detect ubiquitinated substrates. (A) Tryptic digest 
of ubiquitinated substrates gives rise to Lys-iso-Gly-Gly adducts on substrate fragments, which 
can be identified by mass spectrometry. (B) Immunoprecipitation with antibodies specific for the 
Lys-iso-Gly-Gly adduct can be ised to enrich tryptic fragments for those containing adducts (Xu 
et al., 2010).  
 
 
RBBP6 orthologues appear to be present in all eukaryotic genomes, in many 
cases at single copy number, but not at all in prokaryotes. Bioinformatic 
analysis of orthologues from a number of eukaryotic genomes has revealed the 
presence of a number of previously-characterised domains as shown in Figure 
1.4. All eukaryotic genomes appear to contain at least the DWNN domain, zinc 
finger domain and RING finger domain, but higher eukaryotes also contain 
longer C-terminal extensions, as shown in Figure 1.4.  
(B) (A) 
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Figure 1.4 Domain organisation of RBBP6 orthologues in and various eukaryotic 
genomes. All eukaryotes contain at least the DWNN domain, zinc knuckle domain and RING 
finger domains. Higher eukaryotes contain C-terminal extensions, including p53- and pRb-
binding domains as well as an SR domain similar to those found in splicing factors (Adapted 
from Pugh et al., 2006). 
 
 
In many organisms more than one protein isoform is expected to be generated 
from each RBBP6 gene by alternative splicing or the use of alternative 
promoters. In humans, for example, four different isoforms have been identified: 
isoform 1 consists of 1792 amino acids and has a molecular weight of 201,6 
kDa, isoform 2 consists of 1758 amino acids and has a molecular weight of 
197,3 kDa and isoform 4 contains 952 amino acids and has a molecular weight 
of 106,0 kDa. Isoform 3, which consists of 118 amino acids and has a molecular 
weight of 13.2 kDa, is expressed from an alternate promoter and consists of the 
first 100 residues of full length RBBP6, including the DWNN domain, followed 
by an unique 18 residue tail which is not present in any of the other isoforms 
(Genbank: NP_008841, Genbank: NP_061173, Genbank: NP_116015). 
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RBBP6 was originally identified on the basis of its binding to pRB by Sakai and 
co-workers (Sakai et al., 1995) who screened a Lambda ZAPII cDNA 
expression library using pRb as a probe. A protein which was later found to 
correspond to residues 150-1146 of RBBP6 was isolated and called RBQ-1 
(Rb-binding Q-protein-1). This protein was found to bind to hypo-
phosphorylated pRb but not to hyper-phosphorylated pRb, leading the authors 
to suggest that it may function as an oncogene by opposing the tumour 
suppressive effects of hypophosphorylated pRb. They also showed that the 
binding of RBQ-1 was disrupted by E1A (Adenovirus Early Region 1A), which 
suggests that RBQ-1 binds to the physiologically important pocket region of 
pRb.  
 
Using a similar methodology but with p53 as a probe, Simons and co-workers 
identified the mouse protein p53 Associated Cellular protein-Testes derived 
(PACT), which was subsequently found to correspond to residues 207-1792 of 
RBBP6. In addition to interacting with p53, it was also found to interact with 
pRb. PACT was found to bind to wild-type p53, but not to transcriptionally-
inactive mutants such as R273H. PACT was also shown to localise in nuclear 
speckles where splicing factors and splicing-associated Sm proteins are known 
to localise (Simons et al., 1997). 
 
An independent study by Witte and Scott (1997) screened a 3T3 cDNA λgt11 
library using an AC88 monoclonal antibody which specifically detects both 
proliferation-related proteins (P2Ps) and Hsp90. They identified a protein 
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subsequently shown to correspond to residues 199-1972 of RBBP6 (see Figure 
1.5), which they named Proliferation Potential Related Protein (P2P-R). Witte 
and Scott showed that expression of P2P-R is significantly repressed during 
terminal differentiation of cells (Witte & Scott, 1997).  
 
 
Figure 1.5 Full length human RBBP6 and partial human and mouse proteins identified in 
various studies. DWNN13 is the 13 kDa form, also known as isoform 3, which is translated 
from an alternative transcript transcribed from an alternate promoter. The C-terminal 18-amino 
acid residues of DWNN13 are not present in the other three isoforms, all of which are generated 
from the same transcript by alternative splicing. (Adapted from Pretorius et al., 2011)  
 
 
A study by Vo and co-workers in 2001 identified MpeI as the yeast homologue 
of human RBBP6, and showed that it was closely involved in 3’-processing in 
yeast (Vo et al., 2001). MpeI was found to form part of the Cleavage and 
Polyadenylation Factor (CPF) of Saccharomyces cerevisiae and to be 
necessary for 3’-end cleavage and polyadenylation processing of mRNA 
transcripts in yeast. Lee and More subsequently showed that the first three 
domains of MpeI (DWNN, zinc knuckle and RING finger domains) are essential 
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for correct 3’-end polyadenylation in yeast (Lee & Moore, 2014). Manley and co-
workers have demonstrated that RBBP6 forms part of the 3’-end processing 
complex in humans, which closely mirrors its role in the CPF in yeast. They 
showed that knockdown of RBBP6 directly influences 3’-end processing of 
human mRNA transcripts and that isoform 3 modulates the activity of the full 
length RBBP6 by competing with the DWNN domain of full length RBBP6 (di 
Giammartino et al., 2014).  
 
RBBP6 plays a role in tumourigenesis 
Reports in the literature link RBBP6 to a number of different cancers, including 
colon, breast, prostate, colorectal, pancreatic, bladder, cervical and gastric 
cancers (Khan et al., 2014). RBBP6 is reported to be over-expressed in patients 
with oesophageal (Yotishake et al., 2004), breast (Moela et al., 2014), cervical 
(Mbita et al., 2012), gastric (Morisake et al., 2014), colon (Chen et al., 2013) 
and lung cancer (Motadi et al., 2011) and has been linked to low survival rates 
in all of these. Motadi and co-workers demonstrated in 2011 that RBBP6 
suppresses apoptosis and upregulates cellular proliferation in the context of 
lung cancer (Motadi et al., 2011). Miotto and co-workers reported that depletion 
of RBBP6 leads to DNA damage, cell cycle arrest and slowing down of 
replication forks during DNA replication (Miotto et al., 2014).  
 
RBBP6 forms part of the pre-mRNA splicing machinery due to its localisation in 
nuclear speckles which are the main sites of pre-mRNA processing. Although 
this may suggest a primary role for RBBP6 in mRNA processing, the presence 
 
 
 
 
19 
 
of a RING finger domain and the ubiquitin-like DWNN domain suggested it may 
also play a role in the process of ubiquitination. Using a yeast two-hybrid screen 
with the RING finger domain as bait, Chibi and co-workers identified Y-Box 
Binding Protein-1 (YB-1) and zBTB38 as interactors of RBBP6 and showed that 
RBBP6 had E3 ubiquitin ligase activity against both  (Chibi et al., 2008; Miotto 
et al., 2014). Using the DWNN domain as bait, Kappo and co-workers identified 
heat shock protein HSPA14 and the splicing associated protein Sm-G as 
interactors (Kappo et al., 2011).  
 
Y-box binding protein (YB-1) is a transcription factor that transduces the 
expression of a number of tumour-promoting genes, including MDR1 which 
codes for the multidrug resistance protein P-glycoprotein (Braithwaite et al., 
2006). Nuclear localisation of YB-1 is tightly correlated with aggressiveness and 
poor patient prognosis in a number of cancers (Homer et al., 2005). It is also 
closely associated with mRNA maturation, to the extent that it has been 
identified as an mRNA chaperone (Chen et al., 2000). Chibi and co-workers 
found that RBBP6 interacted with the extreme C-terminus of YB-1 through its 
RING-finger domain and ubiquitinated it both in vivo and in vitro. 
Overexpression of the RING finger domain in HEK293T cells led to dose-
dependent and proteasome-specific suppression of YB-1 levels, suggesting that 
RBBP6 negatively is a suppressor of YB-1 (Chibi et al., 2008). RBBP6 has 
subsequently been shown to ubiquitinate YB-1 in fully in vitro ubiquitination 
assay, using UbcH1 as E2 (Faro, A and Pugh, D.J.R., manuscript in 
preparation).  
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zBTB38 is a transcriptional repressor which represses the replication protein 
MCM10. A study by Miotto and co-workers demonstrated that RBBP6 catalyses 
the ubiquitination and proteasomal degradation of zBTB38 in vivo, independent 
of both p53 and MDM2 (Miotto et al., 2014). Knock-down of RBBP6 in HeLa 
cells using RNA interference led to over-expression of zBTB38, leading to 
suppression of MCM10 and consequent accumulation of DNA damage.  
 
Parkin is an E3 ligase protein implicated in Parkinson’s disease which has 
structural similarities to RBBP6. In addition to a RING finger domain, it contains 
an N-terminal ubiquitin-like domain. Chaugule and co-workers demonstrated 
that the ubiquitin-like domain regulates the ubiquitination activity of Parkin by 
folding over and blocking access to the RING finger domain. In pathogenic 
mutations of Parkin this autoinhibition is disrupted, leading to over-activation of 
Parkins activity (Chaugule et al., 2011).  
 
RBBP6 is a negative regulator of p53 
In 2007 Li and co-workers reported that the RING finger-containing protein 
PACT, which is an alternative name for RBBP6, plays an essential role in 
embryonic growth and development in mice (Li et al., 2007). Following knock-
out of the RBBP6/PACT gene by the insertion of a neomycin resistance gene at 
exons 11-12, heterozygous knock-out (PACT+/-) mice were found to be healthy 
and fertile. However, crosses between PACT+/- and PACT+/- mice gave no 
viable PACT-/- offspring, compared to the expected 25%.  
 
 
 
 
21 
 
 
On further investigation it was found that PACT-/- embryos died after 7.5 days 
(E7.5) and the embryos were developmentally retarded and smaller in size as 
compared to their wild type counterparts. They were also found to possess 
elevated levels of p53 and a large number of apoptotic cells. Suspecting a role 
for p53 in the death of the homozygous mice, Li and co-workers  performed the 
same RBBP6/PACT knock-out in p53 null mice (p53-/-). The p53-/-/PACT-/- 
offspring survived slightly longer (up to embryonic day 11.5) although they were 
still smaller in size compared to wild type mice. They concluded from this that 
RBBP6/PACT plays an essential role in suppression of p53 during 
development. In support of this conclusion, over-expression of exogenous 
PACT in mammalian cells was found to result in increased levels of MDM2-
mediated ubiquitination of p53 and a reduction in the transcriptional activity of 
p53.  
 
Li and co-workers went on to show that endogenous PACT interacts with MDM2 
in U2OS and MCF7 human cell lysates. Over-expression of endogenous PACT 
enhanced the interaction between p53 and MDM2. However over-expression of 
PACT on its own did not lead to reduced levels of p53, whereas it did when 
MDM2was simultaneously over-expressed. However p53 degradation was 
abolished when PACT was over-expressed without the RING finger, even in the 
presence of over-expressed MDM2. Li and co-workers concluded that PACT 
facilitates ubiquitination of p53 by MDM2 but is incapable of ubiquitinating it on 
its own. They hypothesised that RBBP6 may act as a scaffold protein bringing 
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MDM2 and p53 together to facilitate ubiquitination, possibly playing the role of 
an E4 ligase (Li et al., 2007).  
 
In a study by Chen and co-workers, p53 expression levels were found to be 
negatively influenced by upregulation of RBBP6 in advanced colon cancer and 
metastasis (Chen et al., 2013). This was found to be due to its being more 
susceptible to ubiquitination by MDM2 than mis-sense mutated p53. Mutated 
p53 was therefore found to be more stable than wild type p53, possibly due to 
an altered conformation of the protein due to the mis-sense mutation. This 
mutant p53 was said to therefore be unable to be ubiquitinated and degraded 
by MDM2 with the assistance of RBBP6. The authors concluded that both the 
transcriptional and post-transcriptional levels of RBBP6 are elevated in colon 
cancer, linking RBBP6 overexpression to tumour invasion and metastasis 
(Chen et al., 2013).   
 
1.4. p53  
p53 has been dubbed “The Guardian of the Genome” due to its key role in 
coordinating the response of the cell to genotoxic stresses. Figure 1.6 depicts 
the broad range of stress signals impinging on p53 and some of the 
mechanisms through which it responds.  
 
The p53 protein is made up of 393 amino acids, as depicted in Figure 1.7. The 
N-terminus is comprised of a transactivation domain (residues 1-42), which is 
the site of extensive post-translational modification, and a proline-rich region 
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(residues 61-94). The central domain (residues 102-292), also known as the 
“core” domain or the DNA binding domain, binds to a consensus DNA sequence 
within the promoters of target genes. Most clinically-important mutations of p53 
occur within this region and it has consequently been the focus of studies aimed 
at understanding the role of mutations in inactivating p53 activity. The C-
terminus comprises the tetramerization domain (residues 324-355) and the 
regulatory domain (residues 363-393), which is heavily post-translationally 
modified by ubiquitination, acetylation and phosphorylation (Rodriguez et al., 
2000; Bai & Zhu, 2006).  
 
 
Figure 1.6 Activators and effectors of p53 function. A broad range of genotoxic stress 
signals impinge on p53, which responds by initiating signals aimed at halting the cell cycle, 
initiating DNA repair, inhibiting angiogenesis or initiating apoptosis (adapted from Weinberg, R. 
2007). 
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Figure 1.7 Schematic representation of the p53 protein depicting the transactivation domain, 
proline-rich domain, DNA-binding domain, tetramerization domain and the regulatory domain. 
NLS is the nuclear localisation signal and NES is the nuclear export signal (Adapted from Bai & 
Zhu, 2006). 
 
 
p53 functions as a tetramer. This provides an explanation for the observation, 
illustrated schematically in Figure 1.8, that mis-sense mutations of p53 — those 
that change one or two amino acids rather than truncating or deleting the entire 
protein —make up a large fraction of all p53 mutations than in similar proteins 
such as APC, ATM or BRCA1. According to the simple model illustrated in 
Figure 1.9, mutant alleles which abolish the activity of any tetramer in which 
they are incorporated will reduce the overall activity of p53 by a factor of 15/16 
=93% (Weinberg, R. 2007). While this represents an extreme case, the model 
shows how even mild suppression of the activity of the tetramer by mis-sense 
mutants can reduce the activity of p53 by more than the 50% expected for a 
monomeric protein. Hence, mis-sense mutants of p53 are more potent 
suppressors of p53 function than knock-out mutations, which explains why they 
are encountered so frequently in the clinic (Weinberg, R. 2007). 
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Figure 1.8 Mis-sense mutations of p53 make up 75% of all p53 mutations, compared to 4% 
for APC, 28% for ATM and 30% for BRCA1 Weinberg, R. 2007 
 
 
 
 
Figure 1.9 Tetramerization explains the frequency of mis-sense mutations of p53 in the 
clinic. If one of the two alleles is able to form part of the a tetramer but abolishes its activity it 
will reduce the overall activity of p53 by 15/16 =93%, compared to the 50% expected if p53 
were monomeric. (Adapted from Weinberg, R. 2007). 
 
 
p53 affects many pathways within the cell, but one of the most significant is cell 
cycle arrest, largely through its activation of the cell cycle inhibitor p21. Division 
of a cell into its two daughter cells, a process known as mitosis, takes place 
according to a strict sequence of events called the cell cycle, which are depicted 
schematically in Figure 1.10. Duplication of the genome occurs in the S phase 
(‘Synthesis’) and division during the M phase (‘Mitosis’), which are separated by 
resting (‘Gap’) periods denoted G1 and G2 respectively. During G1 the cell 
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makes critical decisions about whether to replicate or differentiate, based in part 
on external inputs such as levels of growth factors and nutrients outside the cell. 
During G2 the cell prepares itself for division into two daughter cells during the 
M phase, making use of various checkpoints to check that everything has 
proceeded correctly during DNA synthesis (Weinberg, R., 2007). 
 
For example DNA damage caused by exposure to radiation results in delays 
during both the G1 and G2 phases of the cell cycle. p53 plays a key role in 
arresting the cell cycle during G1, allowing the DNA repair machinery within the 
cell to initiate repair. The cell cycle then resumes normally once this damaged 
DNA has been repaired. However if the DNA damage is too extensive, the cell 
will undergo apoptosis, which is initiated directly by p53 (Weinberg, R., 2007). 
This happens primarily as a result of p53-driven expression of the cyclin-
dependant kinase inhibitor p21CIP1 which blocks phosphorylation of pRb by 
cyclin-dependent kinases, leading to suppression of the activity of E2F by hypo-
phosphorylated pRb.  
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Figure 1.10 Cell cycle checkpoints ensure quality control as the cell progresses through 
the cycle. A cell has to have completed a stage before progressing to the next stage. If not, the 
cell’s progression is halted and DNA damage either repaired, or cell is degraded if damage is 
too severe (Weinberg, R., 2007). 
 
 
Mutations affecting the stability of p53 
More than 95% of all clinically-occurring p53 mutations lie within the core DNA-
binding domain, as shown in Figure 1.11 (Brown et al., 2009). This impacts the 
function of p53's transcriptional activation activity. Of these, 75% are mis-sense 
mutations. These mis-sense mutations can be further divided into DNA contact 
mutations, which interfere directly with the binding of p53 to the DNA and 
therefore affect its transcriptional activity, and structural contact mutations, 
which affect the stability of the entire p53 protein. Structural contact mutations 
typically exert a dominant negative effect due to the quaternary nature of the 
functional complex, as described earlier (see Figure 1.9) (Brown et al., 2009; 
Weinberg, R., 2007; Liu et al., 2010).  
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Addition of zinc has also been shown to be important in the proper folding of the 
core domain of p53, so mutations which affect the zinc binding, such as C242S, 
H179R, C176F and R175H, are often found in human cancers (reviewed by 
Hoe et al., 2014). In addition, a number of mutations, especially in the N-
terminal domain, affect the stability of p53 by modulating the effect of post-
translational modification such as phosphorylation and ubiquitination. These are 
discussed at more length below. 
 
 
Figure 1.11 Hotspots for point mutations within the human p53 gene. 95% of mutations 
affect the core DNA-binding domain. The amino acid numbers which are frequently mutated are 
indicated above the DNA-binding domain (adapted from Weinberg, R. 2007). 
 
 
 
The difference in free energy between the folded and the unfolded state of a 
protein is known as the free energy of folding. The wild-type p53 core domain 
has a free energy of folding of only 7.5-8.5 kcal/mol at 25 °C and no more than 
2-3 kcal/mol at physiological temperature, with the result that it is only 
marginally stable under physiological conditions. A number of single amino acid 
substitutions are therefore sufficient to lower its stability sufficiently to unfold a 
significant fraction of the protein at 25 °C (Bullock et al., 2001). 
 
 
 
 
 
29 
 
In order to increase the stability of p53 for the purpose of delivering it into cells 
as part of gene therapy, Nikolova and co-workers compared the amino acid 
sequences of p53 homologues from 23 species. By means of four separate 
mutations — M133L, V203A, N239Y and N268D — they managed to increase 
the stability of human p53 from 8.5 to 11.3 kcal/mol at 25 °C without 
compromising its ability to bind DNA (Nikolova et al., 1998). When the crystal 
structure was determined in 2004 the overall structure of the so-called 
“quadruple mutant p53” was found to be unchanged from that of wild type p53 
(Joergher et al., 2004). Due to the poor stability if wild type p53, the quadruple 
mutant was used as a proxy for wild type p53 in some of the investigations 
reported later in this thesis. Since the reported interactions between p53 and 
MDM2 involve primarily the N-terminus of p53, and ubiquitination is reported to 
take place on the C-terminus (see below), the four mutations are not expected 
to affect the ubiquitination behaviour of p53. 
 
Ubiquitination of p53 by MDM2 and MDMX 
Regulation of p53 level is very important; levels which are too high may result in 
ectopic apoptosis and levels which are too low may result in failure to avoid the 
consequences of genotoxic stress. Post-translational modifications are covalent 
additions of certain groups to a protein which alter its conformation or its 
activity, but are not coded for by the gene. Common post-translational 
modifications include addition of a phosphate group (phophorylation), of an 
acetyl group (acetylation), of a methyl group (methylation), of a carbohydrate 
chain (glycosylation) or one of a number of small proteins, of which the most 
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important is ubiquitin (ubiquitination). Ubiquitination of p53 by MDM2 leads to its 
targeting to the proteasome and subsequent degradation. Phosphorylation of 
the N-terminal transactivation domain by stress-induced kinases such as ATM 
and Chk2 leads to protection of p53 from ubiquitination by MDM2, leading to a 
rapid rise of p53 levels and induction of the anti-genotoxic response (Hock & 
Vousden, 2013; Pant & Loranzo, 2014). 
 
The major target for p53 ubiquitination is the C-terminus. Of the last 30 amino 
acids on the C-terminus of p53, six — K370, K372, K373, K381, K382 and K386 
— are lysine residues and potential sites for ubiquitination (see Figure 1.12). In 
a study by Rodriguez and co-workers single and multiple substitutions of lysine 
for arginine were generated (Rodriguez et al., 2000). When the lysines were 
individually mutated to arginine no effect on the stability of p53 was observed, 
but when all six were substituted, degradation of p53 catalysed by MDM2 did 
not occur (Rodriguez et al., 2000). It has subsequently been found that other 
lysines elsewhere in p53 are also able to target p53 for degradation, since even 
a truncated form of p53 without its C-terminus is still able to be ubiquitinated by 
MDM2 (Pant & Loranzo, 2014). 
 
MDM2 was the first E3 ligase shown to catalyse degradation of p53 in vitro 
(Honda et al., 1997). However it was subsequently questioned whether MDM2 
was able to catalyse poly-ubiquitination of p53 in fully in vitro ubiquitination 
assays, or whether it was restricted to multiple mono-ubiquitination (Lai et al.,  
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Figure 1.12 Sites on p53 modified by neddylation (Ne), sumoylation (Su) and 
ubiquitination (Ub) and the corresponding E3 enzymes catalysing which elicit these 
modifications (Adapted from Brookes & Gu, 2011). 
 
 
 
2001). MDMX was subsequently identified as a partner for MDM2 that could 
potentially activate MDM2 to poly-ubiquitinate p53. 
 
MDMX is a close structural homologue of MDM2 which nevertheless lacks the 
E3 ligase activity of MDM2. Both MDM2 and MDMX form homodimers in 
solution through their respective RING finger domains; MDM2 and MDMX were 
subsequently shown to also form heterodimers, again through their RING finger 
domains, and the heterodimer complex was shown to have more poly-
ubiquitination activity than the MDM2 homodimer (Wang et al., 2011).  
 
Although poly-ubiquitination of p53 by GST-MDM2 had been previously 
reported in the literature (Lai et al., 2001) in 2011 Wang and co-workers showed 
that His6-MDM2 could only mono-ubiquitinate p53 (Wang et al., 2011). Wang 
and co-workers concluded that since GST is well known to form homodimers in 
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solution; GST was therefore artificially enhancing the poly-ubiquitination activity 
of GST-MDM2 by promoting its dimerisation (Wang et al., 2011). 
 
The combination of MDM2/MDMX has subsequently been shown to also 
catalyse poly-ubiquitination of p53 with the ubiquitin-like protein Nedd8, in a 
process called Neddylation. Neddylation occurs on three C-terminal residues of 
p53, resulting in loss of its transcriptional activity and nuclear export ability as 
shown in Figure 1.11 (Hock & Vousden, 2013). 
  
E2 ligases known to be responsible for p53 ubiquitination 
As described above, E2 acts as an adaptor between the activating enzyme E1 
and the substrate-specific E3. The first E2 enzymes identified for p53 
ubiquitination were the UbcH5 family by Honda and co-workers in 1997 (Honda 
et al., 1997). Saville and co-workers established that UbcH5a, b and c together 
with E2-25K (also known as UbcH1 or Hip2) are capable of ubiquitinating p53 
together with MDM2 in vitro (Saville et al., 2004). UbcH1 is widely known to be 
expressed in mammalian tissues and is has been shown to synthesize 
unanchored poly-ubiquitin chains leading to protein degradation in vitro. The 
core domain of this protein was shown to be crucial in its activity and its 
specificity (Haldeman et al., 1997). UbcH5b and UbcH5c have been well 
studied and shown to share 88-89% homology in their amino acid sequence 
with UbcH5a (Jensen et al., 1995). 
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E2s were always thought of as simple “ubiquitin-carriers”, but have recently 
been shown to play an important role on determining the length and topology of 
the growing ubiquitin chain. These E2s are crucial in chain elongation as they 
determine whether a lysine residue in the ubiquitin or the substrate will receive 
the next ubiquitin molecule. They are therefore also responsible for determining 
the linkage of the growing ubiquitin chain, ultimately deciding the fate of the 
target protein. E2s are also responsible for controlling the processivity if the 
growing ubiquitin chain. The processivity is the number of ubiquitin molecules 
which can be transferred to the growing chain of ubiquitins in one round of 
association with the substrate. The higher this rate of processivity, the greater 
the likelihood that this chain will be long enough to be recognised by the 26S 
proteasome (Ye & Rape, 2009; David et al., 2011).  
  
E4 ubiquitin ligases for p53 (CBP, p300, Ube4b, Gankyrin) 
The existence of an E4 was first proposed by Koegl and co-workers (Koegl et 
al., 1999) as a fourth enzyme involved in poly-ubiquitin chain formation; they are 
proposed to catalyse the attachment of the C-terminus of a ubiquitin moiety to a 
lysine on another ubiquitin, but not to a substrate lysine. Consequently a 
defining characteristic of an E4 is that it can only catalyse poly-ubiquitination of 
already mono-ubiquitinated substrates. 
 
A number if proteins have been reported to act as E4s for p53. Shi and co-
workers showed that CREBS Binding Protein (CBP) and its paralogue p300 
were able to extend chains initiated by MDM2. The N-termini of p300 and CBP 
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have been shown to harbour the E3 and E4 activities of these proteins (Shi et 
al., 2009).Wu and co-workers showed that Ube4b was also able to extend 
chains initiated by MDM2 (Wu et al., 2011). Wu et al., (2011) investigated 
Ube4b as an E4 in the regulation of p53. Ube4b was identified in this study to 
be a U-box containing protein which enabled degradation of p53. They 
discovered that both MDM2 and Ube4b were only capable of mono-
ubiquitinating p53 when either of these proteins were knocked-down in H283 
cells respectively. They performed two-step assays in which p53 was firstly 
mono-ubiquitinated with MDM2 and then allowed to be poly-ubiquitinated with 
Ube4b. Ube4b was found to not be a molecular clamp in the interaction of 
HDM2 and p53 like that of the E4 Yin-Yang 1 (Wu et al., 2011). Yin Yang 1 was 
found to enhance the poly-ubiquitination of p53 by MDM2 and also increase the 
affinity of MDM2 towards p53. It also binds to p300 and recruits it in its 
campaign to poly-ubiquitinate p53 (Hock & Vousden, 2014). Gankyrin is an E4 
known to associate directly with a subunit of the 26S proteasome and control 
the ubiquitin ligase activity of MDM2 (Hock & Vousden, 2014). 
 
1.5.  Objectives of this project 
Li and co-workers have established that RBBP6 plays a central role in 
suppression of p53 during development, activating MDM2 to poly-ubiquitinate it 
and causing its degradation in the proteasome (Li et al., 2007). The first 
objective of this project was therefore to use in vitro ubiquitination assays to 
investigate the role of RBBP6 in the ubiquitination of p53 in more detail. This 
involved recombinant expression and purification of all of the required proteins, 
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including E1, a number of E2s, various forms of ubiquitin, different fragments of 
RBBP6, MDM2 and a number of forms of p53, and using them to set up fully in 
vitro ubiquitination assays with p53 as substrate and MDM2 or RBBP6 as E3. 
Because full length RBBP6 is not suitable for heterologous expression in 
bacteria, an N-terminal fragment denoted R3 was used as a proxy for RBBP6 in 
these assays. 
 
The second objective was to establish if RBBP6 enhances the ubiquitination 
activity of MDM2 or whether RBBP6 is capable of poly-ubiquitinating p53 on its 
own. The third, and related, objective was to establish whether poly-
ubiquitination of p53, produced either by RBBP6 acting alone or in cooperation 
with MDM2 was able to cause degradation of p53 in the proteasome, and 
whether it corresponds to lysine48-linked poly-ubiquitination or some other form 
of linkage.  
 
The fourth objective was to assess whether the ubiquitin-like DWNN domain of 
RBBP6 plays any role, either stimulatory or suppressive, in ubiquitination of 
p53. This was carried out by replacing R3 in ubiquitination assays with a shorter 
fragment excluding the DWNN domain and denoted R2.   
 
The presentation of results begins by describing a sub-project whose aim was 
to generate a DNA plasmid for expressing isoform 3 of RBBP6, also called 
DWNN13, fused to the C-terminus of the monomeric enhanced Green 
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Fluorescent Protein, (mEGFP) for use by co-workers in immunofluorescence 
microscopy studies. 
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CHAPTER 2 
Materials and Methods 
 
A list of suppliers, general stock solutions and buffer preparations can be found 
in the Appendix 
 
 
2.1.  Bacterial strains 
Escherichia coli strain MC1061  
F- araD139 D(ara-leu) 7696 galE15 galK16 D(lac)X74 rpsL (Strr) hsdR2 (rK_ mK+) 
mcrA mcrB1. This strain was used to produce plasmid DNA. 
 
Escherichia coli strain BL21 (DE3)pLysS 
F- ompT gal dcm lon hsdSB(rB
- mB
-) λ(DE3) pLysS(cmR). This strain was used to 
express recombinant proteins. It contains a chromosomal copy of the lambda 
DE3 sequence (λ(DE3)) encoding RNA polymerase from phage T7, and is 
therefore suitable for use with the pET family of protein expression plasmids. 
 
Escherichia coli strain Codon Plus  
B F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3) endA Hte [argU proL Camr] 
[argU ileY leuW Strep/Specr]. This strain also contains λ(DE3) and is therefore 
a suitable host for pET vectors. 
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2.2. Antibodies used 
 
 Anti-p53 primary sc-6243 (Santa Cruz Biotechnology, Inc., CA, USA, 
Rabbit polyclonal raised against full length human p53. 
 Anti-rabbit secondary (HRP-conjugated) 
sc-2313 (Santa Cruz Biotechnology, Inc., CA, USA) 
Donkey anti-rabbit secondary (HRP-conjugated) 
 
2.3.  Antibiotic selection 
For experiments with E. coli containing ampicillin- or kanamycin-resistant 
plasmids, transformed cells were plated on nutrient agar (Merck, Darmstadt, 
Germany) containing 100 μg/ml ampicillin (Sigma Aldrich, Missouri, USA) or 25 
μg/ml kanamycin (Sigma Aldrich, Missouri, USA). Selection was maintained 
during growth in liquid culture by the inclusion of the appropriate antibiotic at the 
same concentration. 
 
2.4.  Bacterial transformation  
Competent cells were first thawed on ice for 15 minutes. Then 50-500 ng of the 
plasmid DNA solution was added to 100 μl of the competent cells, gently mixed 
and incubated on ice for a further 30 min. The cells were then heat shocked by 
transfer to a 42 °C heating block for 90 seconds whereeafter, 500 μl of pre-
warmed Luria Bertani (LB) broth (Merck, Darmstadt, Germany)  was added and 
the mixture incubated at 37 °C for an hour to allow for the expression of the 
antibiotic resistance marker. 50-100 μl of the transformed cell suspension was 
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then plated onto LB nutrient agar plates containing the appropriate antibiotic 
which were then incubated overnight at 37 °C. 
 
2.5. Preparation and manipulation of plasmid DNA  
2.5.1. Plasmid isolation  
A single colony of transformed E. coli was inoculated into 5-10 ml of LB 
containing the appropriate antibiotic. The broth was then incubated at 37 °C 
with vigorous shaking overnight after which the cells were pelleted by 
centrifugation at 16000 g for 10 minutes in a fixed angle JA-14 rotor in a 
Beckman bench top centrifuge (Brea, California, USA). Plasmid DNA was 
isolated using the GeneJet Miniprep kit (ThermoFischer Scientific, Waltham, 
Massachusetts, USA), according to the manufacturer’s instructions. DNA 
sequencing was carried out at Inqaba Biotechnical Industries (Hatfield, South 
Africa) and were compared with the expected sequences using the bl2seq tool 
in the BLAST suite (http://www.ncbi.nlm.nih.gov/BLAST/bl2seq/wblast2.cgi). 
 
2.5.2. PCR amplification  
Reactions consisted of 50 ng template DNA, 1x High Fidelity PCR buffer 
(ThermoFischer Scientific, Waltham, Massachusetts, USA), 0.25 mM of each 
dNTP, 2U Phusion™ HF DNA polymerase (ThermoFischer Scientific, Waltham, 
Massachusetts, USA) and 10 pmol of forward and reverse gene-specific 
oligonucleotides, made up to a final volume of 50 μl with deionised water. 
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The reaction mixture was cycled through the following parameters:  
96 °C for 4 minutes (Initial denaturation)  
 
94 °C for 1 minute (Denaturation)  
60 °C 1 minute (Annealing)                  30 cycles 
72 °C for 2 minutes (Extension)  
 
72 °C for 10 min (Final extension)  
 
PCR reaction products were analysed by electrophoresis in 0.8-1% agarose 
gels in 1x TAE. The amplified product was purified away from contaminating 
fragments using the GeneJet Gel Purification kit (ThermoFischer Scientific, 
Waltham, Massachusetts, USA). 
 
2.5.3. Restriction enzyme digests 
Restriction enzyme (ThermoFischer Scientific, Waltham, Massachusetts, USA)  
digests were performed according to the manufacturer’s instructions and using 
the reagents set out in Table 2.1. Table 2.1 shows an example of the set up 
performed for each ligation reaction set up in this thesis. 
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Table 2.1 Example of set-up for restriction enzyme digestion of the pmEGFP 
vector and DWNN13 PCR product for ligation  
Reagent Final Concentration Vector 
pmEGFP 
DWNN13 PCR 
amplicon 
10x  buffer 1x 10 µl 10 µl 
DNA 1 ug 3.14 µl 10 µl 
Restriction enzyme 1 1 U 5 µl 5 µl 
Restriction enzyme 2 1 U 5 µl 5 µl 
Nuclease free water - 76.86 µl 70 5 µl 
 Total     100 µl     100 µl 100 µl 
 
 
2.5.4. Agarose gel electrophoresis of DNA  
DNA fragments were analyzed by electrophoresis on 0.8-1% agarose gels and 
visualised under UV light using GR Green stain (Inqaba Biotechnological 
Industries, South Africa). Gels were prepared by adding the required volume of 
1x TAE to the appropriate mass of electrophoresis grade agarose. The agarose 
was boiled and then cooled to 55 °C followed by the addition of GR Green to a 
final concentration of 0.5 μg/ml after which it was poured onto a gel-casting tray. 
The appropriate molecular weight marker (Solis biodyne 1 kB marker (Tartu, 
Estonia) or O’GeneRuler 1 kb marker (ThermoFischer Scientific, Waltham, 
Massachusetts, USA) was loaded in the first lane to show the sizes of the 
bands. The DNA was visualized at 300 nM using the UVP BioSpectrum Imaging 
System (Upland, California).  
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2.5.5. Cloning of DNA fragments 
PCR amplifications were designed to incorporate flanking restriction sites to 
facilitate directional cloning into plasmids digested with the same enzymes. 
Generally 20-25 ng of cloning vector was used for the ligation with 4-8 ng of 
PCR product. Ligations were set up in 20 µl reaction volumes containing 1x 
buffer and 1.0 Weiss unit of T4 ligase (ThermoFischer Scientific, Waltham, 
Massachusetts, USA). The ligation reactions were incubated at room 
temperature for 1 hour after which T4 ligase was inactivated at 70 °C for 5 
minutes. 10 µl of the ligation mixture was used to transform 50 µl of E. coli 
MC1061 competent cells after which 900 µl pre-warmed LB both was added. 
25-50 µl of the transformation mixture was plated on LB agar plates containing 
100 μg/ml ampicillin or 25 µg/ml kanamycin and incubated overnight at 37 °C.  
 
Several isolated colonies were picked, inoculated into 25 ml of LB broth 
containing 100 μg/ml ampicillin or 25 µg/ml kanamycin and grown overnight at 
37 °C. The cells were harvested and plasmid DNA isolated using a Genejet 
plasmid isolation kit (ThermoFischer Scientific, Waltham, Massachusetts, USA) 
according to the manufacturer’s instruction. Putative transformants were then 
validated using double restriction digest as described in Section 2.5.3 to release 
the cloned insert. In certain cases colony-PCR was used to detect the presence 
of cloned insert, using the same PCR primers used to amplify the insert out ot 
the template.  
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2.6.  Large scale expression of recombinant proteins 
E. coli cells transformed with the appropriate expression plasmid were grown 
overnight at 37 °C on LB nutrient agar plates containing the appropriate 
antibiotic. In the morning a single E. coli  colony was picked and inoculated into 
25 ml of LB and allowed to grow overnight with the appropriate antibiotic at 37 
°C on a rotary shaker.  
 
The culture was scaled up to 1 L with LB containing the appropriate antibiotic 
and allowed to grow until the OD600 was between 0.4-0.6. 30 minutes prior to 
induction, 100 µM ZnSO4 was added to the culture to ensure proper folding of 
zinc-binding proteins. Induction of protein expression was carried out by adding 
isopropyl β-D-1-thiogalactopyranoside (IPTG) (Inqaba Biotechnical Industries, 
Hatfield, South Africa) and incubating the culture overnight using the conditions 
set out in Table 2.2. 
 
Following induction, bacterial cells were harvested and pelleted at 4 °C for 15 
minutes at 4000 g. The supernatant was discarded and the cell pellet re-
suspended in 30 ml extraction buffer containing protease inhibitor cocktail 
tablets without EDTA. Cells were lysed immediately or else frozen at -20 °C for 
later processing.  
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 Table 2.2 Expression conditions for proteins used in this work 
Expression construct Protein expressed 
Temperature after 
induction 
IPTG  concentration for 
expression 
pGEX-6P2-p53 GST-p53 25 °C 1 mM IPTG 
pGEX-4T3-MDM2 GST-MDM2 25 °C 0.5 mM IPTG 
pET15b-p53 His-p53 WT 25 °C 1 mM IPTG 
pET28a-p53-QM His-p53 QM 25 °C 1 mM IPTG 
pGEX-6P2-R3 GST-R3 25 °C 1 mM IPTG 
pET15a-ubiquitin HA-Ubiquitin 30 °C 0.5 mM IPTG 
pGEX-6-P2-UbcH1 GST-UbcH1 25 °C 1 mM IPTG 
 
 
2.7.  Protein extraction and preparation of crude cell lysate 
Frozen cell pellets were thawed on ice and cells were lysed by sonication in 20-
30 ml protein extraction buffer. Cells were sonicated in 30 second intervals 
followed by 30 seconds incubation on ice, repeated for a total of 5 minutes. 
Following sonication, the cells were pelleted at 4300 g for 30 minutes at 4 °C.  
 
2.8. Protein purification 
2.8.1. GST-glutathione affinity chromatography 
The column was prepared by addition of 5-15 ml of glutathione agarose slurry 
(ABT Bead Technologies, Madrid, Spain) into an empty gravity flow columns 
(Bio-Rad, Hercules, California). The column was washed with 3 column 
volumes (CV) of 1 M NaCl and then equilibrated with 5 CV of wash buffer. 
Crude lysate was added to the column and the flow-through collected after 
which the column was washed with 3 CV of wash buffer. Bound proteins were 
eluted with elution buffer containing 20 mM reduced glutathione (Sigma Aldrich, 
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Missouri, USA). Fractions were analysed by SDS-PAGE, as described in 
Section 2.11. 
 
Fractions containing fusion proteins were pooled and transferred to SnakeSkin® 
Pleated Dialysis Tubing (MWCO 3500Da) (Thermo Scientific, Massachusetts, 
USA). After addition of 3C protease, produced in-house as a GST fusion 
protein, the dialysis tube was placed in 2 litres of 1x PBS with 1 mM DTT and 
cleavage allowed to proceed overnight at 4 °C. In the morning the contents of 
the dialysis bag was returned to the glutathione agarose column in order to 
remove the cleaved GST, uncleaved fusion protein and GST-3C protease which 
was retained by the beads, with the target protein being collected in the flow-
through.  
 
As an alternative to gravity flow, GST was also removed using three GSTrap 
columns (GE Healthcare, Little Chalfont, UK) connected in series, operated 
under control of a ÄKTA FPLC Purification System (GE Healthcare, Little 
Chalfont, UK).  
 
2.8.2. Nickel ion affinity chromatography 
Empty gravity flow columns were packed with Ni-NTA affinity beads (Sigma-
Aldrich, Missouri, USA) according to the manufacturer’s instructions. The 
column was washed with 3 column volumes (CV) of 1 M NaCl and then 
equilibrated with 5 CV of wash buffer. The crude lysate was then added to the 
column and the flow through collected. The column was washed with 3 CV of 
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wash buffer, before the bound proteins were eluted with the appropriate buffer. 
300-400 mM imidazole was used to elute the His6-tagged proteins. Fractions 
were analysed by SDS-PAGE, as described in Section 2.11.  
 
2.8.3. Cation exchange chromatography  
Wild type ubiquitin, which was expressed without an affinity tag, was purified 
using a method which takes advantage of its high stability at low pH, returning 
to neutral pH using cation exchange chromatography. Glacial acetic acid 
(Merck, Darmstadt, Germany) was added to clarified lysate until it turned cloudy 
(approximately pH 4.5) indicating denaturation of most of the accompanying 
proteins. Denatured proteins were pelleted by centrifugation and the 
supernatant transferred to SnakeSkin® Pleated Dialysis Tubing. The solution 
was dialysed against 2 litres of 20 mM sodium acetate, pH 4.5, overnight and 
subsequently transferred to a 3 ml self-packed POROS S20 cation exchange 
column, following pre-equilibration of the column with sodium acetate, pH 4.5. 
The flow through was collected and the column washed with 2 column volumes 
of sodium acetate, pH 4.5. Bound proteins were eluted from the column using 
PBS (pH7.4) containing increasing concentrations of NaCl. 
 
2.9. SDS-PAGE analysis of proteins  
Protein samples were separated on SDS-polyacrylamide gels (SDS-PAGE) 
according to Laemmli’s method (Laemmli, 1970). 16% separating gels were 
prepared using 4 ml 40% acrylamide: bis-acrylamide stock (Merck, Darmstadt, 
Germany), 2.63 ml separating buffer, 40 µl 10% ammonium persulphate (Merck, 
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Darmstadt, Germany), 105 µl 10% SDS, 7.5 µl TEMED (Sigma Aldrich, 
Missouri, USA) and 3.2 ml distilled water. The stacking gel was prepared from 
0.75 ml 40% 37:5:1 polyacrylamide, 25 µl 10% APS, 50 µl 10% SDS, 1.25 ml 
stacking buffer, 5 µl TEMED and 3.05 ml distilled water.  
 
Protein samples were prepared by adding an equal volume of 2x SDS sample 
buffer to the samples, followed by boiling (placing in a dry heating block at 95 
°C) for 5 minutes. 12-20 μl of each sample was loaded on the SDS-PAGE gel 
and the samples were separated by electrophoresis using the Bio-Rad Mini-
Protean system operated at 150 V. Proteins were visualised by incubating the 
gel in Coomassie (Sigma Aldrich, Missouri, USA) staining solution for 30 
minutes on an orbital shaker and then destained overnight in destaining 
solution. Alternatively, the gel was processed for Western blot analysis, as 
described below. 
 
2.10.  Western blotting of proteins  
Proteins separated on SDS-PAGE were incubated for 5 minutes in 1x ProSieve 
Ex transfer buffer (Lonza, Basel, Switzerland). Pall Biotrace PVDF membrane 
(New York City, USA) was activated in 50 ml Absolute Ethanol (Merck, 
Darmstadt, Germany) and proteins were then transferred to it by semi-dry 
transfer using the Bio-Rad Transblot® Turbo™ transfer system (Bio-Rad, 
Hercules, California) for 10-12 minutes. Following transfer, the membrane was 
blocked with 1% casein in PBS-T (1x PBS containing 0.1% Tween 20) and then 
incubated with the appropriate antibodies for 1-2 hours. The membrane was 
washed three times for 5 minutes each with PBS-T and then incubated with the 
 
 
 
 
48 
 
appropriate HRP-conjugated secondary antibody. The membrane was again 
washed three times for 5 each minutes with PBS-T and then incubated in 5 ml 
Clarity Western ECL Substrate (Bio-Rad) and viewed using a UVP BioSpectrum 
Imaging System (UVP, Upland, California). 
 
2.11.  Purification of proteasome out of human cell lysate 
MCP21 hybridoma cells expressing antibodies targeting the α2-subunit of the 
human proteasome were purchased from Sigma-Aldrich (Missouri, USA) and 
serum was produced from them by Ms Ania Szmyd-Potapczuk, a co-worker in 
the laboratory. The antibody was coupled to Affi-Gel® beads (Bio-Rad, 
Hercules, California) as follows: 500 µl of Affi-Gel® beads were washed with an 
equal volume of cold distilled water, centrifuged at 4300 g and the supernatant 
discarded. The beads were then incubated with 2.5 ml of HEPES (pH 7.5) for 1 
hour at 4 °C with rolling after which 100 µg of anti-proteasome antibody was 
added and allowed to incubate at 4 °C overnight. In the morning the beads were 
centrifuged at 4 °C at 4300 g at 4 °C and the supernatant discarded. The beads 
were quenched with 1 M Tris pH 8.0 (to prevent the binding of any additional 
proteins to the beads) and allowed to incubate for a further 30 minutes at 4 °C 
before being washed with 3 CV of 10 mM citric acid pH 8.0 and 3 CV of 1x PBS. 
The beads were then stored in 2 ml 1x PBS containing 0.02% NaN3.  
 
Lysates from cultured human A549, HepG2 or HeLa cells were kindly provided 
by Ms Andronica Ramaila, a co-worker in the laboratory. 2.5 mM Mg-ATP was 
mixed with 100 μg cell lysate which was then incubated with 100 μl Affi-Gel® 
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beads coupled to the anti-α2 antibody as described above, overnight at 4 °C 
with rolling. The following day the beads were pelleted for 5 minutes at 5000 g 
at 4 °C and then washed three times with binding buffer as above before being 
resuspended in 200 μl binding buffer with 5 mM Mg-ATP and stored at 4 °C. 
 
2.12.  Ubiquitination assays  
Lysate-based ubiquitination assays were set up by adding HepG2 or HeLa cell 
lysates to purified recombinant proteins. Fully in vitro assays were set up by 
omitting the cell lysates. Reaction mixtures were made up as set out in Table 
2.3 or as otherwise stated (following a modified protocol established by Honda 
et al., 1997). Briefly, reactions were performed using buffer containing 1x PBS, 
5 mM Mg-ATP, 10% glycerol, 0.5 mM ZnSO4 unless otherwise stated. Reaction 
mixtures were briefly vortexed, centrifuged and then incubated overnight at 37 
°C with shaking. Reactions were stopped by acetone precipitation, as follows: 
400-800 μl acetone was added to each tube and incubated at -20 °C for 30 
minutes following which the precipitate was pelleted at 5000 g at 4 °C for 10 
minutes. The pellets were dried at 37 °C and 2x SDS-PAGE sample buffer 
added. The proteins were separated on SDS-PAGE and visualised by Western 
blotting using the appropriate antibodies.  
 
2.13. Immunoprecipitation of proteins  
1 µg anti-p53 antibody (sc-6243, Santa Cruz Biotechnologies, Inc., CA, USA) 
was added to each reaction tube and allowed to incubate at 4 °C with rolling for 
15 minutes. During this time, 100 µl of Protein A/G PLUS agarose beads (sc-
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2003, Santa Cruz Biotechnology, Inc., CA, USA) was washed three times at 
13 000 rpm with 500 µl IP buffer. Beads were resuspended in 150 µl IP buffer 
and 20 µl beads added per assay tube and allowed to incubate for 1 hour at 4 
°C with rolling. The beads were then washed three times with IP buffer as 
before. 
 
2.14.  In vitro two-step E4 ubiquitination assay 
The assay was carried out following the protocol of Wu and co-workers (Wu et 
al., 2011). It requires an E3 (MDM2 in this case) to mono-ubiquitinate the 
substrate (p53 in this case), and a putative E4 (R3 in this case) to poly-
ubiquitinate the mono-ubiquitinated substrate. 
 
 The assay was performed by setting up an initial ubiquitination reaction (Step 
1) using MDM2 as E3 and p53 as the substrate. Exact quantities for each 
reaction in Step 1 are set out in Table 2.4. After 1 hour p53 was 
immunoprecipitated using the protocol described in Section 2.14, incubating the 
reaction with anti-p53 antibodies for 1 hour at 4 °C. Step 2 was a ubiquitination 
reaction using R3 as E3/E4 and the Protein A/G beads containing the 
‘monoubiquitinated p53’ as substrate. Exact quantities for each reaction in Step 
2 are set out in Table 2.5. The ubiquitination reaction was incubated at 37 oC 
overnight. Note that while reaction 5 corresponds to the assay as described 
(MDM2 in Step 1 and R3 in Step 2), reaction 6 corresponds to the reverse order 
(R3 in Step 1 and MDM2 in Step 2). Following completion of the reaction, the 
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beads were washed with 1x PBS, SDS sample buffer was added and the 
results visualised by Western blot analysis as before.  
 
Table 2.3 Reagents used in the in vitro ubiquitination assay 
 
 
 
 
 
Table 2.4 Setup for 2-step ubiquitination assay: Step 1 
 
Components 
 
      1 2 3 4 5 6 
p53 + + + + + + 
MDM2 - - - + + - 
R3 - - - - - + 
E1, E2, Ubiquitin, ATP, 1x PBS buffer - + + + + + 
PBS + + + + + + 
 
Reaction volume 
 
 100 µl 
 
   100 µl 
 
 100 µl 
 
 100 µl 
 
100 µl 
 
 100 µl 
 
 
 
Reagent Experimental reaction Control reaction(s) 
Cell lysate 50-100 μg 50-100 μg 
E1 0.35 μM 0.35 μM 
E2 (UbcH5a) 2 μM 2 μM 
E3 (MDM2 & R3 &/or R2) 1- 10 μM - 
Substrate (p53) 1-5 μM 1-5 μM 
MG132 (proteasome inhibitor) 1 mM 1 mM 
HA-Ubiquitin 1 mM 1 mM 
Buffer 50-70 μl 50-70 μl 
1x PBS Made up to 150-200 μl Made up to 150-200 μl 
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Table 2.5 Setup for 2-step ubiquitination assay: Step 2 
 
Components 
 
1 2 3 4 5 6 
Protein A/G beads (p53~Ub) + + + + + + 
MDM2 - - - - - + 
R3 - - + - + - 
E1, E2, Ubiquitin, ATP, 1x PBS buffer - + + + + + 
PBS + + + + + + 
 
Reaction volume 
 
100 µl 
 
100 µl 
 
100 µl 
 
100 µl 
 
100 µl 
 
100 µl 
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CHAPTER 3 
 
Cloning, expression and purification of proteins for in vitro 
ubiquitination assays 
 
3.1. Introduction 
In order to establish if RBBP6 is capable of ubiquitinating p53 alone or if it only 
enhances MDM2-mediated p53 ubiquitination, in vitro ubiquitination assays 
were carried out using proteins produced recombinantly in bacteria. This 
chapter documents the expression and purification of these proteins, as well as 
generation of a number of expression constructs by molecular cloning. 
 
Assays were designed to detect ubiquitination of p53 directly as higher 
molecular weight bands on SDS-PAGE gels, visualised by Western blotting with 
anti-p53 antibodies. An alternative approach, directly detecting ubiquitin using 
anti-ubiquitin antibodies, although potentially more sensitive, was not used 
since molecules other than the substrate, including the E3s, are known to be 
poly-ubiquitinated and could therefore lead to false results. 
 
p53 is a notoriously unstable protein that is highly sensitive to proteolysis when 
expressed in bacteria. Three different constructs were used for expression of 
full-length p53 in an attempt to overcome this problem: GST-tagged wild type 
p53 expressed from a pGEX-6P-2 vector, N-terminally His6-tagged wild type 
p53 expressed from a pET15b vector and the M133L/V203A/N239Y/N268D 
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quadruple mutant reported by Fersht and co-workers (Nicklova et al., 1998). 
The latter construct was codon-optimised for expression in bacteria and 
expressed from a pET28a vector with an N-terminal His6 tag. 
 
MDM2, a well-established E3 ligase and the putative E3 ligase RBBP6 were 
investigated in the study. Since full length RBBP6 is over 200 kDa in size and 
unlikely to express stably in bacteria, a shortened fragment containing the first 3 
domains — the DWNN domain, the zinc knuckle domain and the RING finger 
domain — and named R3, was expressed and used in this study. An even 
shorter fragment containing only the second and third domains — the zinc 
knuckle and RING finger domain — and named R2, was also used.  
 
Bacterial expression of other proteins documented in this chapter include the E2 
enzymes UbcH1 and UbcH13 as well as ubiquitin and the ubiquitin-K0 mutant, 
in which all lysines have been replaced by arginines. Expressed samples of a 
number of other proteins were kindly donated by co-workers in the laboratory; 
these include the E1 enzyme, the ubiquitin-K48R mutant, His6-MDMX and the 
E2 UbcH5a from Dr Andrew Faro, E2s UbcH5b and UbcH5c from Dr Mautin 
Kappo, E2s Mms2 and UbcH7, as well as the MultiDSK protein, from Ms 
Tephney Hutchinson and R2 from Ms A’tieyah Salie. 
 
An important issue raised in the literature concerned whether attached GST can 
artificially enhance the ubiquitination activity of MDM2 against p53 by artificially 
enhancing homo-dimerisation (Wang et al., 2011). Samples of R3 and MDM2 
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were therefore produced with and without attached GST in order to test whether 
there was any significant enhancement in their ubiquitination potential. 
 
The first section of this chapter describes subcloning of isoform 3 of RBBP6 into 
the mammalian expression construct pmEGFP. This sub-project was conducted 
on behalf of a co-worker in the laboratory and does not form part of the in vitro 
ubiquitination studies. It nevertheless represents an important reagent for the 
broader understanding of the localisation of RBBP6 within mammalian cells and 
it is therefore appropriate that its construction is documented in this thesis. 
 
3.2. Generation of pmEGFP-DWNN13 construct for immunofluorescence 
microscopy 
RBBP6 is known to be independently expressed in vivo in at least two isoforms: 
the 200 kDa full length protein, also known as isoform 1, and a 13 kDa isoform 
known as isoform 3 which consists almost entirely of the ubiquitin-like DWNN 
domain found at the N-terminus of isoform 1. Due to its molecular weight we will 
also refer to isoform 3 as DWNN13. Sequencing of a previous pEGFP-
DWNN13 construct revealed that the DWNN domain had been inserted in the 
negative orientation, rendering it useless; we therefore set out to amplify it from 
the incorrect construct and clone it into pmEGFP-C1 in the correct orientation. 
pmEGFP-C1, which was a gift from Dr. Benjamin Glick (Addgene plasmid No. 
36412), encodes a monomeric form of Enhanced Green Fluorescent Protein 
(EGFP), obtained by introduction of the monomerising A206K mutation into the 
EGFP gene. The map of pmEGFP-C1 is shown in Figure 3.1 with the Multiple 
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Cloning Cassette (MCC) indicated by a yellow box. Target proteins are fused to 
the C-terminus of mEGFP.  
  
Oligonuclotide primers were designed incorporating XhoI and KpnI restriction 
sites in the forward and reverse primers, respectively, as shown in Figure 3.2. 
5’-TAA and 5’-TGA stop codons were introduced into the reverse primer 
immediately preceding the KpnI site. Since the XhoI site is not “in frame with the 
promoter”—the frame is CǀTCGǀAG, rather than ǀCTCǀGAGǀ—two additional 
nucleotides (CT) were incorporated into the forward primer between the XhoI 
site and the first codon (TCC) of DWNN13. The initial methionine was omitted 
from DWNN13, yielding an amino acid sequence beginning with SCVHYK... 
 
DWNN13 was successfully amplified, as shown in Figure 3.2(b), and cloned 
between the XhoI and KpnI sites of pmEGFP-C1. Nine putative positive 
colonies were screened by colony-PCR using the primers shown in Figure 
3.2(a) and all found to be positive, as shown in Figure 3.2(c). Colonies 8 and 9 
were investigated further by double digestion with XhoI and KpnI, releasing 
inserts of the expected sizes (Figure 3.2 (d)). The sequence was verified by 
direct sequencing (Inqaba Biotechnical Industries, Hatfield, South Africa) and 
found to be 100% in agreement with the expected sequence (see Appendix). 
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Figure 3.1. Plasmid map of pmEGFP-C1 with the restriction enzymes used for cloning circled 
in red. Target proteins are fused to the C-terminus of mEGFP. XhoI is not in frame with the 
promoter, with the result that additional bases must be inserted between the XhoI site and the 
beginning of the target sequence in order to re-establish the frame. 
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Figure 3.2 Cloning of DWNN13 into pmEGFP-C1 (a) Primer sequences used for amplification 
of DWNN13 into pmEGFP-C1. The XhoI and KpnI restriction sites are indicated by the blue and 
orange boxes respectively.The dinucleotide CT, indicated in yellow, was introduced to restore 
the frame of DWNN13 after the XhoI site. Two stop codons are indicated by red boxes. (b) 
Successful amplification of a 290 bp fragment corresponding to DWNN13 (right lane). (c) 
Colony-PCR screening of selected colonies using the specific primers shows that all of them 
contain an insert of the expected size. The positive control used was the original DWNN13 in 
pEGFP construct (d) Double digestion of two selected colonies with XhoI and KpnI releases a 
fragment of the expected size of 290 bp (as indicated). 
 
(a) 
(d) 
(b) (c) 
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3.3. Generation of an expression construct for the E2 UbcH1 
 
Figure 3.3 Plasmid map of pGEX-6P-2 expression vector with restriction enzymes used for 
cloning circled in red.  
 
UbcH1, also known as HIP2 or UBE2K, has been reported to act as a ubiquitin 
conjugating enzyme (E2) for p53, in conjugation with MDM2. A construct coding 
for UbcH1, cloned into the pACT2 vector, was a kind gift from Prof Rachel Klevit 
of the University of Washington, Seattle (Addgene plasmid No: 31436). Forward 
and reverse primers incorporating BamHI and XhoI sites respectively were 
designed as shown in Figure 3.4(a) and used to amplify UbcH1 for ligation into 
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the same sites of the bacterial expression vector pGEX-6P-2. A map of pGEX-
6P2 can be seen in Figure 3.3. In this case the BamHI site is “in frame” with the 
promoter, negating the need for additional bases between the BamHI site and 
the start of UbcHI. Two stop codons (TAA TAA) were inserted immediately 
before the XhoI site.  
 
PCR amplification using the pACT2-UbcH1 template yielded a band of 
approximately 400-500 bp, which corresponds to the expected size of full-length 
UbcH1, as can be seen in lane 1 of Figure 3.4(b). No amplification is seen in 
lane 2, to which no template DNA was added. The PCR product was purified 
and digested with BamHI and XhoI restriction enzymes and ligated into pGEX-
6P-2, following digestion with the same restriction enzymes. Six putative 
positive colonies were screened using colony-PCR using the same primers in 
order to confirm the presence of the expected insert (Fig 3.4(c)); all six amplified 
a band of the same size as the original PCR product (lane 1), confirming that 
they were positive transformants. The positive control was a PCR reaction using 
the original template. No negative control was included in this screen. The 
sequence was verified by direct sequencing (Inqaba Biotechnical Industries, 
Hatfield, South Africa) and found to be in 100% agreement with the expected 
sequence. 
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Figure 3.4 Amplification and PCR-colony screening of UbcH1. (a) Primers used to amplify 
UbcHI from pACT2-UbcH1. The BamHI and XhoI restriction sites are indicated in the pink box 
and green boxes respectively. The start of UbcH1 is indicated in the blue box. Two TTA stop 
codons are indicated by the red box. (b) PCR amplification of UbcH1. A PCR product of about 
500 bp, which corresponds to the expected size of the UbcH1 coding sequence, can be seen in 
lane 1. Lane 2 is the negative control which contains no template DNA. Lane M contains the 
O'GeneRuler 1kb DNA ladder mix (Thermo Scientific, Massachusetts, USA). (c) PCR-colony 
screening of putative transformants for the presence of the UbcH1 insert. Lanes 2-7 are all 
positive for the UbcH1 insert. Lane 1 is the positive control which included the original construct 
pACT2-UbcH1 as template. 
 
(c) 
(a) 
(b) 
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3.4. Generation of expression construct for stabilised p53 quadruple mutant  
A DNA sequence coding for the M133L/V203A/N239Y/N268D mutant of p53, 
codon-optimised for expression in bacteria and flanked by NdeI and BamHI 
restriction sites, was synthesized by Genscript Inc. (Piscataway, NJ, USA.) and 
supplied in a pUC57 vector. The plasmid was transformed into E. coli and 
digested with NdeI and BamHI, which released an insert of the expected size, 
as shown in lane 4 of Figure 3.5(b) (denoted p53-QM, for “p53 quadruple 
mutant”). The insert was then cloned into pET28a; as can be seen from panel 
(a), the NdeI restriction sites was chosen so that the protein would be 
expressed with an N-terminal His6 tag. A 5’-TGA stop codon was included 
immediately before the BamHI site to ensure that the C-terminal His6 tag in the 
vector would not form part of the expressed protein.  
 
Fifteen putative positive colonies were picked and screened by double digestion 
with NdeI and BamHI for the presence of the p53-QM insert, as shown in panel 
(c). An insert of the expected size (1192 bp) was visible in 8 of the 15 colonies, 
of which 2 were subjected to direct sequencing and found to be in 100% 
agreement with the expected sequence (see Appendix). 
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Figure 3.5 Subcloning of the quadruple mutant p53 (p53-QM) from a pUC57 vector into 
the expression vector pET28a. (a) The pET28a vector sequence and multiple cloning 
cassette. Indicated in red are the NdeI and BamHI restriction sites respectively. (b) Agarose gel 
showing preparation of the vector and insert. The undigested pUC57-p53-QM vector can be 
seen in lane 1. Single digestion of the pUC57-p53-QM vector with NdeI and with BamHI can be 
seen in lanes 2 and 3 respectively; double digestion with both NdeI and BamHI released the 
expected p53-QM insert (lane 4). Lanes 5 and 6 contain the pET28A vector, undigested and 
digested with both NdeI and BamHI respectively. (c) Screening DNA preparations from colonies 
1-15 using double digestion with NdeI and BamHI (even lanes) and undigested (odd lanes). The 
released p53-QM insert is clearly visible in lanes 2, 4, 6, 12, 16, 22, 24 and 26. Colonies 8 
(lanes 15 and 16) and 13 (lanes 25 and 26) were selected for sequencing. 
 
(a) 
(c) 
(b) 
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3.5. Expression and purification of three different p53 constructs: GST-p53 (wild 
type), His6-p53 (wild type) and His6-p53-QM (quadruple mutant) 
 
Human p53 was used as the substrate in all in vitro ubiquitination assays. Three 
different expression constructs were tested in an effort to maximise expression 
and minimise degradation.  
 
GST-p53 (wild type) 
A pGEX-6P-2 expression vector containing wild type human p53 was a gift from 
Dr Andrew Faro in our research group. The protein was expressed as a fusion 
with glutathione-S-transferase (GST) and purified using a glutathione-
conjugated agarose column as described in Section 2.9. The protein was 
expressed at low levels (Figure 3.6), so Western blotting using a rabbit poly-
clonal anti-p53 antibody (sc-6243 Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA) was used to confirm the presence of the GST-fusion protein. The 
GST was successfully removed using GST-3C protease (lane 2) and the 
sample returned to the glutathione column following dialysis to remove free 
glutathione. Cleaved p53 was collected in the flow-through (lanes 3-5) and 
appears at the expected size of slightly more than 50 kDa. GST was retained by 
the column and eluted in lanes 6-8, although it is not visible in the p53-detected 
Western blot. The amount of residual GST along with p53 in lanes 3-5 is also 
not apparent from the blot since only p53 is detected. 
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Appreciable levels of low molecular weight degradation products were detected 
in all lanes; note that while full length p53 was not retained by the column, as 
expected, the degradation products leach continuously from the column, as 
would be expected for unfolded protein fragments. Full length p53 forms a 
single tight band at its expected molecular weight, which suggests that it is 
folded and intact; unfortunately it was found to degrade rapidly following 
removal of the GST tag, making it difficult to use in the subsequent in vitro 
assays. 
 
 
 
Figure 3.6 Western blot showing cleavage and purification of GST-p53. Western blotting 
was used due to low levels of expression. The primary antibody used was polyclonal anti-p53 
antibody raised against full length p53 (dilution 1:1000). Lane 1 contains GST-p53 following 
affinity purification out of bacterial lysate using glutathione agarose, prior to cleavage with 3C 
protease. Lane 2 is the same sample following cleavage using 3C protease—the band 
corresponding to the fusion protein is almost completely depleted, leaving a band at around 50 
kDa corresponding to p53 and a number of smaller fragments which are detected due to the 
fact that the antibody was raised against full length p53. All of the full length p53 is found in the 
flow through (lane 3 or the washes  lanes 4 and 5, but not in the elution (lanes 6-7)). However, 
since this is a p53-detected Western blot it does not reveal how much GST remains in lanes 2-5 
along with the full length p53.  
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His6-p53 (wild type) 
A pET15b plasmid coding for wild type p53 with an N-terminal His6 tag was a 
gift from Prof Cheryl Arrowsmith, University of Toronto, Canada (Addgene 
plasmid number: 24859). The protein was expressed and purified using 
immobilised nickel ion affinity chromatography, as described in Sections 2.10. 
Expression levels of His6-p53 were still not high as shown using SDS-PAGE 
(lane 7, Figure 3.7), but were generally better than those of GST-p53 (a 
Western blot was not necessary to show the expressed levels as it was visible 
directly on an SDS-PAGE gel). Nevertheless, they were deemed sufficient for 
ubiquitination assays as the end-point analysis by Western blotting can detect 
as little as femtograms of protein. His6-p53 wild type appears to be running 
slightly low on the SDS-PAGE in Figure 3.7, possibly due to the marker on the 
gel running slightly askew. However, the Western blot of this sample shown in 
Figure 4.2 confirms that it does migrate at the expected size. 
 
His6-p53-QM 
Construction of a pET28a plasmid coding for the p53 quadruple mutant (p53-
QM) is described in Section 3.4. p53-QM was expressed and purified using 
immobilised nickel ion affinity chromatography, as shown in Figure 3.8. In our 
hands this protein was found to express in low levels, as is apparent in lanes 7-
9, and to be highly susceptible to degradation, even immediately after 
purification. Nevertheless this construct has subsequently been used 
extensively by a co-worker in the laboratory to reproduce many of the results 
presented in this thesis (Dr Andrew Faro, manuscript in preparation),  
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Figure 3.7 SDS-PAGE gel showing expression and purification of wild-type His6-p53 
using nickel ion affinity chromatography. Lane 1 contains the insoluble fraction and lane 2 
the soluble fraction prior to purification. Lane 3 contains the flow through and lanes 4 and 5 the 
column washes with 20 mM imidizole to suppress non-specific binding to the column. Lanes 6-8 
contain elutions with 400 mM imidizole. Lane 9 is the cleaning step with 1M imidizole and 1M 
NaCl. The band eluting at approximately 50 kDa in lane 7 corresponds to p53. This band 
appears to migrate a little faster than expected, but the Western blot in Figure 4.2 confirms that 
it is indeed p53. 
 
and generation of the construct has therefore contributed significantly to 
understanding of the process of ubiquitination of p53 by RBBP6. 
 
In summary, all three methods of expressing p53 were found to be susceptible 
to extensive degradation, both pre- and post-lysis. Overall, the most stable form 
was found to be His6-p53 
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Figure 3.8 SDS-PAGE gel showing small-scale expression and purification of the 
quadruple mutant p53-QM. Low levels of p53-QM can be seen in the elution fraction in lane 7. 
Lane 1 contains the insoluble fraction and lane 2 the soluble fraction. Washes with 10 mM 
imidizole to remove any non-specific adhering of proteins are shown in lanes 4 and 5 
respectively. Elution with 200mM imidizole is shown lane 6 and with 400mM imidizole is shown 
in lanes 7-9. Elution 4 also has additional 1M NaCl to clean any residual proteins off the column. 
 
 
 
3.6. Expression and purification of ubiquitin-ligating enzymes MDM2 and R3 
A pGEX-4T3 expression vector coding for GST-MDM2 was a gift from Mien-
Chie Hung, University of Texas, Houston, USA (Addgene plasmid number 
16237). A pGEX-6P-2 vector coding for the R3 fragment of RBBP6 (residues 1 
– 335) was previously cloned by a co-worker in our laboratory. This fragment 
contains the RING finger domain known to be essential for enhancing the 
ubiquitination activity of RBBP6 against p53 (Li et al, 2007), and was shown to 
be suitable for soluble expression in bacteria (Dr Andrew Faro, PhD thesis, 
University of the Western Cape 2011).  
 
GST-fusion proteins were expressed and purified using glutathione agarose 
affinity chromatography as described in Section 2.9. Elution of GST-MDM2 can 
be seen in Figure 3.9, lanes 6-8, migrating at the expected size of 
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approximately 90 kDa. MDM2 is known to migrate at a higher effective size than 
would be expected from its true molecular weight of 54 kDa (Cheng & Cohen, 
2007). Elution of GST-R3 can be seen in Figure 3.10, lanes 6-7, migrating 
higher than the expected size of approximately 65 kDa (full length protein 38 
kDa + GST 27 kDa). Significant evidence of lower molecular weight degradation 
products can be seen in both cases, but especially for GST-MDM2. Depending 
on the required application, GST was either left in place or removed using 
thrombin protease, in the case of GST-MDM2, or 3C protease in the case of 
GST-R3. Levels of expression of both of these proteins were sufficient for use in 
in vitro assays; however both were susceptible to on-going degradation post-
purification. Lower bands below each protein are simply due to degradation 
products and are not contaminating proteins. Further purification was not shown 
as the degradation became increasingly worse when upon further handling of 
these proteins and degradation products were not an issue for the application of 
the proteins. 
 
Figure 3.9 SDS-PAGE gel showing expression and purification of GST-MDM2. The box 
indicates elution of GST-MDM2 from the glutathione agarose matrix following addition of free 
glutathione. Lane 1 contains bacterial lysate prior to induction with IPTG and lane 2 the lysate 
following induction. Lane 3 is the flow through and lanes 4 and 5 are the column washes. Lanes 
6-8 are the GST-MDM2 elutions with 20 mM reduced glutathione. Lane 9 is the final wash 
elution with 20 mM reduced glutathione and 1M NaCl.   
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Figure 3.10 SDS-PAGE gel showing expression and purification of GST-R3. Lane 6-8 
shows the elution of GST-R3 by 20 mM reduced glutathione. Lane 1 is the insoluble fraction 
and lane 2 the soluble fraction. Lane 3 is the flow through. Lanes 4 and 5 are the column 
washes. Lane 9 is the final wash elution by 20 mM reduced glutathione and 1M NaCl. 
 
 
 
3.7. Expression and purification of various ubiquitin conjugating enzymes (E2s) 
and ubiquitin 
Purification of UbcH1 
Generation of an expression construct for the E2 enzyme GST-UbcH1 was 
described above. The fusion protein was expressed in E.coli, retained on a 
glutathione agarose column and subsequently eluted with free glutathione as 
shown in Figure 3.11(a), lanes 6-8. Cleavage with 3C protease produced two 
bands on SDS-PAGE of very similar molecular weight, corresponding to GST 
(25 kDa) and UbcH1 (23 kDa) respectively. After being returned to the 
glutathione agarose column the lower band was found in the flow through, 
confirming that it was UbcH1 (Fig 3.11(b), lanes 3 & 4), whereas the upper band 
was retained on the column and eluted with free glutathione, confirming that it 
was GST (lanes 7 & 8). A small amount of residual GST remaining in the 
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UbcH1 sample was removed using three 5 ml GSTrap columns (GE Healthcare 
Life Sciences) connected in series, operated using an ÄKTA Protein Purification 
System (GE Healthcare Life Sciences). In order to retain the UbcH1 in a soluble 
form, a high salt buffer was required. A buffer of 400 mM NaCl and 50 mM Tris 
was made up and the protein was dialysed into the high salt buffer overnight at 
4 °C. The triple GSTrap column was pre-equilibrated with the buffer of 400 mM 
NaCl and 50 mM Tris prior to purification. The protein was loaded onto the 
column and 5 CV washes of 1 ml each were collected which were expected to 
contain the highly purified protein of interest (Fig 3.12(a) fractions 5-13; (b) 
lanes 3-7). The elution buffer was made up of 20 mM reduced glutathione in 
400 mM NaCl and 50 mM Tris buffer. 3 ml elutions were collected which were 
expected to contain residual GST (lane 9) and GST-fusion protein only. 
Selected fractions were analysed by SDS-PAGE. Note that while GST is not 
apparent in lane 1 of Fig 3.12(b) because it was too dilute, it does appear in 
lane 9 as a result of the concentrating effect of affinity chromatography. The 
dilute band visible below UbcH1 in lane 3-7 represents a degradation product of 
UbcH1. The intensity of this band typically increased with time following 
purification, while that of the upper band decreased, which is consistent with 
proteolytic removal of a portion of UbcH1. Since UbcH1 contains a C-terminal 
ubiquitin-like domain in addition to the typical E2-like domain, it is possible that 
this corresponds to proteolytic removal of the ubiquitin-like domain. 
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Figure 3.11 SDS-PAGE gels showing expression, purification and cleavage of GST-
UbcH1. (a) Glutathione affinity purification of GST-UbcH1, which can be seen eluting in lanes 5-
8 following immobilisation on the glutathione agarose column. Free GST is also observed, from 
which we conclude that there was a degree of cleavage of the linker between GST and UbcH1 
either before or after lysis. Lane 1 is the soluble fraction before purification and lane 2 is the flow 
through. Lanes 3 and 4 are column washes. The elutions 1 to 5 with 20mM reduced glutathione 
are shown in lanes 5-9 respectively.  (b) Cleavage of GST-UbcH1 with GST-3C protease can be 
seen in lane 2, which should be compared with the uncleaved sample in lane 1. Cleavage 
produces two very similarly sized bands corresponding to UbcH1 and GST. The cleaved UbcH1 
was not retained on the column due to its GST tag being cleaved off and elutes in lanes 3 and 4 
with the column washes. The GST protein elutes in lanes 7-9 with 20 mM reduced glutathione. 
The marker used was BioRad Precission Plus unstained marker. 
(a) 
(b) 
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Figure 3.12 Removal of residual GST from UbcH1 using three 5 ml GSTrap
™
 columns 
connected in series.  (a) Chromatogram from an ÄKTA purification system showing the flow 
through (labelled “lanes 3-7”) and the elution fraction (labelled “lane 9”) (b) SDS-PAGE 
confirming that GST, which is eluted from the column (lane 9) corresponds to the higher of the 
two bands, whereas UbcH1, which is found in the flow through (lanes 3-7) corresponds to the 
lower band. All residual GST has been removed from the flow through. The even lower band in 
lanes 3-7 corresponds to a degradation product of UbcH1. The marker used was BioRad 
Precission Plus unstained marker. 
 
 
 
(a) 
(b) 
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Purification of UbcH13 
An expression plasmid coding for the E2 enzyme UbcH13 in a pET24 vector 
was a gift from Prof Rachel Klevit, University of Washington, Seattle, USA. 
UbcH13 was expressed with a C-terminal His6 tag, and was purified using 
gravity-flow immobilised nickel affinity chromatography. Elution of large 
quantities of UbcH13 from the column is shown in lane 8 of Figure 3.13. The 
higher molecular weight contaminants seen in lane 8 were subsequently 
partially removed using a HisTrap™ purification column on the ÄKTA Protein 
Purification System (data not shown). Unfortunately the majority of the protein 
was lost due to precipitation during this second step purification process; 
however the quantity that remained was deemed more than sufficient for in vitro 
ubiquitination assays. 
 
 
Figure 3.13 Expression and purification of the E2 His6-UbcH13 using nickel ion affinity 
chromatography. Partially purified His6-UbcH13 is seen in lanes 8 and 9 as indicated in the 
black box. Lane 1 shows the insoluble fraction (pellet) and lane 2 is the soluble fraction (lysate) 
prior to purification. Lane 3 contains the flow through and lanes 4 and 5 the column washes with 
20 mM imidizole to suppress non-specific binding to the column. Lane 6 contains the first elution 
with 15 mM imidizole and Lane 7 contains the second elution with 300 mM imidizole. Lane 8 is 
the third elution with 400 mM imidizole and lane 9 the final elution with 2 M NaCl to remove any 
protein still bound to the column. 
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Purification of wild type and K(0) mutant ubiquitin  
Expression plasmids for wild type ubiquitin and the K(0) mutant (all lysine 
residues replaced with arginines) were kind gifts from Prof Rachel Klevit 
(affiliation as above). Both were expressed without an affinity tag and purified 
according to the protocol supplied in Section 2.9.4, which takes advantage of 
the stability of ubiquitin at pH 4.5 to denature and precipitate host proteins. The 
proteins were purified further by cation exchange chromatography at pH 4.5; 
since the pI of both wild type and K(0) ubiquitin as determined by the ExPasy 
ProtParam server are in the vicinity of 6.5, at pH 4.5 they are expected to be 
highly positively charged and therefore retained by the cation column. 
 
Purification of ubiquitin-K(0) is shown in Figure 3.14. As expected, most of the 
ubiquitin was retained by the cation column and eluted with a step-wise gradient 
of NaCl (lanes 4-7); however significant quantities of contaminating host 
proteins were still co-purified. To purify the target protein further, the fractions in 
lanes 4-7 were pooled, dialysed against 1mM PBS to reduce the concentration 
of NaCl and subjected to a further round of purification. The final eluate in 600 
mM NaCl (panel (b), lane 6) is highly purified. This sample was dialysed into 20 
mM sodium acetate for use in in vitro assays. 
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Figure 3.14 SDS-PAGE gel showing the purification of the ubiquitin-K(0) mutant. (a) 
Partial purification of the ubiquitin mutant-K0 mutant is indicated by the arrow in lanes 4-7 This 
initial purification of the ubiquitin mutant was performed after dialysis with 20 mM sodium 
acetate. The soluble fraction is shown in lane 1 and the flow through in lane 2. The column 
washes were combined and produced a sample was taken to produce the result in lane 3. 
Elutions 1-4 were performed with a stepwise gradient of NaCl (50 mM, 200 mM, 400 mM and 1 
M NaCl respectively). (b) Re-purification of ubiquitin mutant-K0. Due to their being a lot of 
contaminating bacterial proteins still present in the partially purified UbcH13 preparation in (a), 
the elutions from lanes 4-7 were pooled and subjected to second round of purification. Large 
quantities of highly pure ubiquitin-K(0) can be seen in lane 6. Lanes 1-3 contain the flow through 
and lanes 4-6 contain the three elutions with 50 mM, 200 mM and 600 mM NaCl respectively.  
 
 
 
(a) 
(b) 
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3.8. Purification of intact proteasomes from human cell lysates  
Intact 26S proteasomes were precipitated from human HeLa cell lysates using 
an antibody raised against the α2 subunit, using lysate prepared from MCP21 
hybridoma cells (Sigma-Aldrich, Missouri, USA) by a co-worker, Ms Ania 
Szmyd-Potapczuk. The antibody was coupled to Affigel beads (Bio-Rad, 
Hercules, California) as described in Section 2.12-2.13. 
 
A Western blot showing successful detection of the purified 26S proteasome is 
shown in Figure 3.15.  A number of background bands are visible in lanes 1-3, 
which are likely to correspond either to cross-reactivity with lysate proteins or to 
heavy and light chains of the anti-α2 antibody, which is expected since the same 
antibody was used for both immunoprecipitation and detection. However the 
presence of additional bands in lane 7 which are not present in lane 2 is 
evidence that α2 subunit has been precipitated. The new bands are in the range 
of 20-40 kDa which is consistent with the mass of the α2 subunit (26 kDa). The 
bands are unlikely to correspond to β-subunits, since they are not likely to be 
detected by the antibody against the α2 subunit. Nevertheless, the fact that at 
least the α2 subunit is present in the immunoprecipitate makes it likely that the 
entire intact proteasome has been precipitated as well. 
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Figure 3.15 Immuno-blot showing purification of the 20S α2-subunit of the 26S 
proteasome from HeLa cell lysate.  Proteasome purified using anti-proteasome antibody 
raised against the α-subunit of the 20S core subunit which was coupled to Affigel® matrix 
beads. Lane 1 is the HeLa human cell lysate. Lane 2 is the Affigel matrix beads coupled to the 
antibody. Lane 3 is the lysate after proteasome purification. Lanes 4 and 5 are the supernatants 
from wash buffers1 and 2 respectively. Lane 6 and 7 are the purified proteasome beads. 
Western blot antibody dilution 1:500 primary, 1:1000 goat-anti mouse secondary (Santa Cruz). 
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CHAPTER 4 
 
In vitro investigation of the ubiquitination of p53 by RBBP6 and 
MDM2  
 
4.1. Introduction 
Studies in knock-out mice suggested that RBBP6 plays a role in facilitating poly-
ubiquitination and degradation of p53 by MDM2. In the same study Li and co-
workers showed that RBBP6 (referred to as PACT in their report) interacts 
directly with MDM2 in U2OS and MCF7 cell lysates. Since RBBP6 had 
previously been shown to interact with p53 via its C-terminus (Simons et al., 
1995), Li and co-workers hypothesised that RBBP6 may function as a molecular 
scaffold, bringing p53 and MDM2 together to catalyse ubiquitination of p53 by 
MDM2 (Li et al., 2007). Using immunoprecipitation they showed that a stronger 
interaction exists between p53 and MDM2 in the presence of RBBP6. They also 
showed that over-expression of Myc-PACT alone in HEK293 cells did not lead 
to a decrease in exogenous Flag-p53, but did lead to a decrease when MDM2 
was co-expressed together with Myc-PACT. Hence they concluded that RBBP6 
does not participate directly in the ubiquitination reaction, but only indirectly by 
facilitating the ubiquitination activity of MDM2 (Li et al. 2007). 
 
At the same time RBBP6 contains its own RING finger domain and has been 
shown to have its own E3 ligase activity against the cancer-associated protein 
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YB-1 and DNA damage-associated protein zBTB38, in both cases leading to 
degradation in the proteasome (Chibi et al., 2008; Miotto et al., 2011). The 
possibility that RBBP6 has its own ubiquitin ligase activity against p53 is 
therefore worthy of more detailed investigation. 
 
We therefore set out to investigate using in vitro assays whether RBBP6 is able 
to mono- or poly-ubiquitinate p53 with or without the assistance of MDM2. Due 
to the (expected) poor solubility of the full length RBBP6 protein, a truncated 
form of RBBP6 consisting of the first 335 amino acid residues was used. This 
fragment was named “R3” because it contains the first three domains of 
RBBP6, namely the DWNN domain, the zinc knuckle and the RING finger. 
Since R3 does not contain the C-terminal region previously characterised as the 
p53-binding domain (Simons et al., 1997), utilising R3 should therefore rule out 
the scaffold mechanism proposed by Li and co-workers. Nevertheless, a protein 
orthologous to human R3 is expressed in all invertebrate eukaryotic genomes 
(see Figure 1.4), which suggests that this fragment may contain most, if not all, 
of the ubiquitination-related activity of the protein. 
 
4.2. R3 is able to ubiquitinate p53 in a partially in vitro system  
As a first step, a partially in vitro ubiquitination assay was set up in which 
human HepG2 cell lysate was used to supply the E1 and E2 enzymes, to which 
bacterially-expressed R3 and/or MDM2 were added. Since endogenous p53 
was not detectable in the lysate (HepG2 are expected to express wild type p53 
(Volmer et al., 1999) which might be quite low for this application as p53 is kept 
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at low levels), bacterially-produced p53 was added and detected by Western 
blot using anti-p53 antibodies. 
 
Due to the expected presence of other endogenous E3 enzymes in the lysate, 
any effect observed using this assay could not be attributed exclusively to R3. 
Nevertheless, the expectation in setting up this assay was that it may provide a 
rapid means of determining whether R3 promotes ubiquitination of p53, either 
directly or indirectly, and whether addition of R3 together with MDM2 leads to 
increased ubiquitination suggestive of cooperative behaviour. It should also 
allow for investigation of whether the resulting ubiquitination was mono- or poly-
ubiquitination and whether it resulted in proteasomal degradation. 
 
Figure 4.1 shows the result of adding GST-R3, or MDM2 (GST tag removed) to 
HepG2 cell lysate. Bacterially-expressed p53 (GST tag removed) was added to 
all lanes except lane 1 and was detected by Western blotting with rabbit poly-
clonal anti-p53 antibody (sc-6243 Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA). p53 was detected as a doublet at approximately 50 kDa. The 
absence of similar bands in lane 1, which contains only lysate, confirms that 
endogenous p53 was not expressed at detectable levels in these cells. 
Bacterially-expressed ubiquitin, E1 and a panel of E2s (UbcH1, UbcH5b, 
UbcH5c, UbcH6, UbcH7, UbcH8 and UbcH13) were added to all lanes except 
lane 1.  
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Figure 4.1 R3 and MDM2 promote the poly-ubiquitination of p53 in the presence of human 
HepG2 lysate (A) GST-R3 (lane 5) and MDM2 (lane 7) catalyses massive ubiquitination of p53 
in the presence of HepG2 lysate, which is not present when exogenous E3 is not added (lane 
3). Unmodified p53, migrating as a doublet at an apparent molecular weight of around 50 kDa, 
can be seen in lanes 2 and 3, to which no exogenous E3 enzymes were added. The absence of 
endogenous p53 in the HepG2 lysate (lane 1) is expected and shows that the p53 in lanes 2-9 
corresponds exclusively to exogenous, bacterially-expressed p53. Omission of proteasome 
inhibitors MG132 and MultiDsk appears to result in a decrease of the poly-ubiquitination (lane 
4), possibly due to degradation of the poly-ubiquitinated p53 in proteasome. However, an 
expected similar effect is not seen in lanes 6 and 8, rendering the results inconclusive. (B) 
Same assay as in (A), but with only MultiDsk added in odd lanes rather than a combination with 
MG132. The same massive poly-ubiquitination is observed when GST-R3 and MDM2 are used 
together, although the evidence for poly-ubiquitinated p53 in lane 8, which contains MultiDsk, as 
compared to lane 7 which contains no MultiDsk, is not convincing. The lack of degradation in 
lane 7 suggests that MultiDsk was either not present or not functional. 
(A) 
(A) 
(B) 
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Lane 5 of Figure 4.1(A) suggests that R3 promotes poly-ubiquitination of p53 in 
HepG2 lysate. A thick smear stretches right up to the top of the Western blot, 
most likely corresponding to poly-ubiquitination of p53, which is not present 
when R3 is not added (lanes 2 and 3). Higher molecular weight bands up to 150 
kDa are typically identified with mono-ubiquitination of p53 on multiple sites 
(Wang et al., 2011); however bands such as these, stretching much higher than 
the top marker band at 150 kDa, are more likely to correspond to poly-
ubiquitination of p53. 
 
Note that this result does not allow the conclusion that R3 is capable of poly-
ubiquitinating p53 on its own. It is possible that R3 cooperates with other 
endogenous E3s present in the lysate, including MDM2. However it does 
confirm the conclusion of Li and co-workers that R3 promotes poly-
ubiquitination of p53. 
 
As expected, MDM2 produces similar high molecular weight smears when 
added to the lysate (lane 7). Here too, the potential presence of other E3s in the 
lysate, such as MDMX, means that this result does not contradict the view that 
MDM2 can only mono-ubiquitinate p53. In addition to other ubiquitination 
enzymes, cell lysate is also likely to contain de-ubiquitination enzymes (DUBs), 
which may reduce the amount of ubiquitination, and 26S proteasomes, which 
may degrade poly-ubiquitinated p53 and lead to a decrease of the high 
molecular weight smears. In an attempt to control for these two effects, 
MultiDsk, a synthetic protein reported to oppose the effects of DUBs and 
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proteasomal degradation, and MG132, which is well known to block the 26S 
proteasome, were added together to odd-numbered lanes. This is expected to 
lead to increased ubiquitination in odd-numbered lanes. While there does 
appear to be evidence for this in the case of GST-R3 (compare lanes 4 and 5), 
the effect appears to be the wrong way around in the case of MDM2 (lanes 6 
and 7). When GST-R3 and MDM2 are added together the poly-ubiquitination is 
still present but there is no considerable increase suggestive of cooperation 
between them (lane 9). Nevertheless Fig 4.1(A) provides strong evidence that 
R3 promotes poly-ubiquitination of p53 in cell lysates. 
 
Figure 4.1(B) shows a repeat of the result in (A), but this time using only 
MultiDsk in odd-numbered lanes to determine whether MultiDSK was capable of 
performing its concentrating effect of poly-ubiquitinated proteins and preventing 
degradation without the aid of MG132. It could only concentrate if a pull down 
was performed – was anything like that done? Again there is evidence of heavy 
poly-ubiquitination when R3 and MDM2 are present together (lanes 7 and 8), 
but much less evidence when they are used separately (lanes 3-6). There may 
be evidence of more poly-ubiquitination when MultiDsk is present (lane 8), 
suggesting that degradation has taken pace in lane 7, but it is not convincing. 
The lack of any effect from MultiDsk suggests that MultiDsk was either not 
present in the expected concentration or was not functional. 
 
The R3 used in these assays was a fusion with GST. MDM2 was expressed as 
a fusion with GST, but the GST was subsequently removed using the thrombin 
protease site present in the expression vector. A number of authors have 
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warned that the presence of GST may artificially enhance the poly-ubiquitination 
activity of GST-MDM2 by stabilising the homo-dimeric state (Hadelman et al., 
1997; Wang et al., 2011). Since R3 forms a homodimer in solution (P. M 
Maumela and D.J.R. Pugh, manuscript in preparation), it is possible that GST 
artificially enhances the ubiquitination activity of GST-R3 in the same manner. 
However size exclusion data suggests that the strength of the homodimer is 
already sufficiently strong that GST is unlikely to have much effect on the 
stability of the R3 homodimer (P. M Maumela and D.J.R. Pugh, unpublished 
data). Un-tagged R3 and MDM2 were therefore used wherever possible, 
although the inherent instability of both E3s meant that this was not always 
possible. These two Figures in 4.1 (A) and (B) are the representative results 
presented in the repetition of these assays in seven attempts – what does this 
mean – that you did them 7 times and they gave different results in the other 5? 
 
4.3. Optimisation of fully in vitro ubiquitination assays 
The previous assays were conducted using a mammalian cell lysate to provide 
essential associated enzymes such as E1 and E2s. As a first step in setting up 
full in vitro ubiquitination assays, protocols were bench-marked against the 
MDM2/MDMX system, which is known to produce poly-ubiquitination when both 
MDM2 and MDMX are present, but only mono-ubiquitination when MDM2 is 
used on its own (Wang et al., 2011). The E2s selected for this screening were 
UbcH1, UbcH5a, UbcH5b and UbcH5c to provide a variety as the preferred E2 
would be selected from this pool. His6-p53 was used and detected using a 
rabbit polyclonal antibody, as previously described. As can be seen from Figure 
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4.2, addition of increasing amounts of GST-MDM2 and a fixed amount of 
MDMX led to a dose-dependent increase of high molecular weight bands above 
100 kDa. We concluded that bacterially expressed MDM2 and MDMX are 
successfully producing poly-ubiquitination of p53 in a fully in vitro system and 
that a MDM2 concentration of 1 µM was sufficient for detectable ubiquitination.  
 
Figure 4.2 MDM2 and MDMX titration to find the optimal conditions for p53 ubiquitination. 
A mix of GST-MDM2 and MDMX was titrated with concentrations are indicated above. Lane 1 
contains only the substrate p53 and the PBS buffer with E1. Lane 2 contains p53 and the PBS 
buffer with E1 and ubiquitin. Lane 3 contains the same as lane 2 with an E2 mix of UbcH1, 5a, 
5b and 5c. Lane 4 contains the same as lane 3 with 0.5µM of the E3 GST-MDM2. Lanes 5-10 
contain the same as lane 3 with increasing concentrations of the combination of GST-MDM2 
and MDMX.  
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A similar titration assay was carried out using GST-MDM2 and GST-R3, and 
Figure 4.3 shows some evidence of dose-dependent ubiquitination of p53 by 
GST-MDM2/GST-R3 extending to above 150 kDa. Disappointingly this was far 
less than previous assays. Despite being repeated several times, the quantity of 
ubiquitination remained low. It is possible that one of the many components in 
our assays was not functional, not present in sufficient quantities or degraded. 
However it does suggest that the amounts of ubiquitination seen in many of our 
assays are nevertheless significant, since they are comparable with the effect 
seen for the standard system of MDM2/MDMX. 
 
 
4.4. UbcH5a is the preferred E2 for in vitro poly-ubiquitination of p53 by GST-
MDM2 and GST-R3 
The in-lysate assays shown in Figure 4.1(A) and (B) indicate that R3 is able to 
promote poly-ubiquitination of p53. However these assays do not indicate 
whether R3 is sufficient, or whether any other proteins are required for this 
ubiquitination. 
 
In order to identify one or more E2s which work in combination with R3 to 
ubiquitinate p53 in vitro, an E2 screen was conducted using a number of 
bacterially-expressed E2s. The screen was performed using bacterially His6-
tagged p53, which was tested in an attempt to circumvent the serious 
degradation found with GST-tagged p53. 
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Figure 4.3 GST-MDM2 and GST-R3 titration to find the optimal conditions for p53 
ubiquitination. Lane 1 contains only the substrate p53 and the PBS buffer with E1. Lane 2 
contains p53 and the PBS buffer with E1 and ubiquitin. Lane 3 contains the same as lane 2 with 
the E2 UbcH5a. Lane 4 contains the same as lane 3 with 0.5 µM of the E3 GST-MDM2. Lane 5 
contains the same as lane 3 with 0.6 µM GST-R3. Lanes 6-10 contains the same as lane 3 with 
increasing concentrations of the combination of GST-MDM2 and GST-R3.  
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1 µM of GST-MDM2 and 1 µM of GST-R3 was added to each lane in Figure 
4.4, along with 0.35 µM of E1, 2 µM of each E2 and 1 mM HA-ubiquitin and 1 
µM His6-p53.  
 
Although the samples appear to have run anomalously on the gel, there is 
nevertheless clear evidence that UbcH5a (lane 5) and UbcH5c (lane 7) are the 
most effective E2s for ubiquitinating p53, both producing high molecular weight 
smears right to the top of the gel. Consistent with this conclusion, the band 
corresponding to unmodified p53 appears lighter in the lane containing UbcH5a 
(lane 5) than in all the others, as would be expected if a significant fraction of 
p53 were migrating at higher molecular weight. UbcH5c appears to be not as 
effective as UbcH5a in ubiquitinating p53, since the band corresponding to 
unmodified p53 band is not as light in lane 7 as it is in lane 5. However the 
majority of the p53 remained unmodified at 53 kDa. The other E2s did not show 
ubiquitination activity with this MDM2/R3 combination.  
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Figure 4.4 In vitro E2 screen using His6-p53 confirms that UbcH5a acts as E2 with E3s 
GST-MDM2 and GST-R3 to poly-ubiquitinate p53. Lanes 1-9 contain 10 µM each of GST-R3 
and GST-MDM2. Lane 1 contains ubiquitin with no E2s. Lane 2 contains a mixture of all the E2s 
used without ubiquitin. Lane 3 contains an E2 mix with ubiquitin. Lanes 4-10 all contain 
ubiquitin. Lanes 2-9 contain 2 µM each of the E2s shown in the key. High molecular weight 
smears in lanes 5 and 7 show that UbcH5a and UbcH5c are able to catalyse poly-ubiquitination 
of p53 by GST-MDM2 and GST-R3. 
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Up to this point, in the in vitro assays R3 has been shown to produce 
ubiquitination of p53 in combination with MDM2. In order to test whether it has 
its own E3 activity against p53 a fully in vitro assay was set up using 2 µM 
UbcH5a as the E2. Lanes 3 of Figure 4.5 suggests that R3 is able to mono-
ubiquitinate p53, with higher molecular weight species apparent at least up to 
150 kDa. It is possible that the bands extends further, but the poor resolution of 
this 16% self-cast SDS-PAGE gel makes it difficult to discriminate between high 
molecular weight bands. The effect is similar to that produced by GST-MDM2 
alone (lane 4). Similar high molecular weight bands are seen in lane 2, which 
contains no E3, but they are much fainter than when R3 is present. When GST-
MDM2 is added jointly with R3 the density of the ubiquitination increases; 
whether this is due to cooperation between MDM2 and R3 or simply the 
combined effect of the two E3s working individually is not clear from this assay. 
Densitometry could be used to quantify signals produced through Western 
blotting, however this method of quantification was not investigated in this 
thesis. 
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Figure 4.5 R3 is able to ubiquitinate p53 independently of MDM2 using UbcH5a in an in 
vitro assay. Lane 1 is non-modified p53. Lane 2 is p53 with the reagents for ubiquitination 
without the E3s. Lane 3 has R3 (cleaved of its GST tag) added in addition to the reagents in 
lane 2. Lane 4 GST-MDM2 with the reagents in lane 2. Lane 5 contains both R3 and GST-
MDM2.  
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4.5. Ubiquitination by a combination of R3 and MDM2 leads to enhanced 
ubiquitination of p53 and proteasomal degradation in vitro 
The results of the previous section suggest that R3 may be able to catalyse 
poly-ubiquitination of p53 in conjunction with UbcH5a as E2. If so, then it may 
also be expected to catalyse proteasomal degradation of p53, provided the 
poly-ubiquitination involved lysine-48 internal linkages. UbcH5a is known to 
catalyse lysine-48 linked poly-ubiquitination with a number of different E3s (Kim 
et al., 2015). To test this hypothesis, intact proteasomes were 
immunoprecipitated from A549 human cell lysates and added to all tubes in the 
in vitro ubiquitination reactions. The p53, R3 and MDM2 used in this assay were 
all tagged with GST. 
 
The results are shown in Figure 4.6(A). Lanes 2 and 3 show evidence of poly-
ubiquitination produced by GST-R3 and GST-MDM2 respectively, with bands 
stretching up at least to 150 kDa and possibly higher, which are not present in 
the absence of E3 (lane 1). When GST-R3 and GST-MDM2 are added together 
both the un-modified p53 and the higher molecular weight bands almost 
completely disappear (lane 4), suggesting that poly-ubiquitinated p53 has been 
degraded in the proteasome. Crucially, in the presence of the proteasome 
inhibitor MG132 (lane 5) both the unmodified and higher molecular weight 
species of GST-p53 are restored completely, which is clear evidence that the 
reduction in lane 4 is due to degradation by the proteasome. Due to no MG132 
controls being included for lanes 2 and 3, it cannot be concluded that there was 
no degradation in these lanes; nevertheless it is noticeably less than that seen 
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in lanes 4 and 5. p53 degradation products are clearly seen in all the lanes due 
to the instability of GST-p53. 
 
 
Figure 4.6 Enhanced degradation using both GST-R3 and GST-MDM2 in vitro (A) In vitro 
assay showing degradation when both GST-R3 and GST-MDM2 are used. All lanes contain 
purified proteasome from A549 human cell lysate, GST-p53, E1, and a cocktail of E2 including 
UbcH1, UbcH5a, UbcH5b, UbcH5c, UbcH6 and UbcH8. Lane 1 is GST-p53 only. In addition, 
lane 2 contains additional GST-R3, lane 3 contains GST-MDM2, lane 4 contains both GST-R3 
and GST-MDM2 and lane 5 contains GST-MDM2 and GST-R3 together with MG132 to inhibit 
the purified proteasome. (B) An independent repeat of the assay in panel (A), including the 
same components. 
(A) 
(B) (A) 
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This conclusion is confirmed by the repeat assay shown in Figure 4.6(B). As 
before, both un-modified p53 and higher-molecular weight bands are reduced 
when GST-R3 and GST-MDM2 are used together (lane 4), and re-appear when 
MG132 is added (lane 5). Furthermore, p53 is not reduced when GST-R3 or 
GST-MDM2 are used individually. These results suggest strongly that GST-R3 
and GST-MDM2 are individually incapable of catalysing degradation of GST-
p53, but that when used together they produce poly-ubiquitin capable of 
causing degradation of p53. This appears to confirm previous in vivo reports 
that RBBP6 cooperates with MDM2 in catalysing poly-ubiquitination and 
degradation of p53. 
 
An objection may be raised against the previous result that the substrate and 
the E3s all have GST attached. According to the argument put forward by Wang 
and co-workers (Wang et al., 2011) it is possible that GST enhances the 
ubiquitination activity of R3 and MDM2 by promoting their dimerisation. 
Alternatively, the GST attached to the substrate may promote recruitment of 
either or both of the E3s. In reply to this objection, it can be pointed out that 
GST-MDM2 was not able to cause degradation of GST-p53 (lane 3 of panel A), 
despite the presence of GST on both proteins. 
 
Despite the above argument, in order to eliminate all uncertainty resulting from 
the presence of GST was attempted to reproduce the results in Figure 4.6 
following removal of the GST from the substrate and E3s. However, this proved 
very difficult due to the instability of all three proteins following removal of the 
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GST tag. Instead of GST- or His6-tagged wild type p53, we therefore generated 
an expression construct for the quadruple mutant form of p53 reported by 
Joergher and co-workers (Joergher et al., 2004), and expressed it with an N-
terminal His6 tag (His6-p53-QM). Following removal of the GST tag the amounts 
of MDM2 recovered dropped significantly, and no consistent ubiquitination could 
be generated using MDM2, leading us to the conclusion that the amount of 
active MDM2 had been reduced to ineffective levels. However Western blots 
detecting MDM2 to show this directly were not undertaken. 
 
Figure 4.7 shows the result of an in vitro assay using His6-p53-QM as substrate 
and either GST-MDM2 or R3 (no GST tag) as E3. UbcH5c was used as E2 in 
all lanes. His6-p53-QM appears as a doublet at around 50 kDa, as seen in 
previous results. The band consistently seen at around 100 kDa in all lanes is 
considered to be an artefact and subsequent work has shown that this band is 
not present when a different anti-p53 antibody is used (A. Faro, unpublished 
data). In the absence of ubiquitin there is very little evidence of ubiquitination, 
as would be expected (lanes 1-4). However addition of either R3 (lane 7) or 
GST-MDM2 (lane 5) yielded clear evidence of poly-ubiquitination corresponding 
to molecular weights substantially greater than 150 kDa. 
 
Significantly more ubiquitination was produced when R3 and GST-MDM2 were 
used together (lane 10), a conclusion supported by the disappearance of 
unmodified p53. In fact the level of ubiquitination appears to be significantly 
greater than the sum of the amounts produced by R3 and GST-MDM2 alone, 
suggesting that the effect is cooperative rather than simply additive. Lane 9 
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contains the same reagents as lane 10, with the addition of proteasome purified 
from A549 cell lysates.  
 
 
 
Figure 4.7 Ubiquitination of p53-QM using a combination of R3 (no GST tag) and GST-
MDM2 leads to enhanced ubiquitination and results in proteasomal degradation of p53-
QM. Showing fully in vitro ubiquitination and degradation assay of the p53 quadruple mutant. All 
lanes contain p53-QM and ubiquitination buffer.  Lanes 1, 3, 5, 7 and 9 all contain purified 
proteasome and the others do not. Lanes 1-4 do not contain ubiquitin and 4-12 contain 
ubiquitin. Lanes 3 and 4 also contain both R3 and GST-MDM2. Lanes 5 and 6 contain GST-
MDM2 with and without proteasome respectively. Lanes 7 and 8 contain GST-R3 with and 
without proteasome respectively. Lanes 9 and 10 contain both R3 and GST-MDM2 with and 
without proteasome respectively.  
 
 
While not as dramatic as the result in Figure 4.6, the significant reduction of 
high molecular weight bands in lane 9 compared to lane 10, strongly suggests 
that p53 is being degraded by the proteasome. Comparison of lanes 5 and 6 
suggests that poly-ubiquitination catalysed by GST-MDM2 may be susceptible 
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to degradation, although there is no evidence that the same is true for R3 (lanes 
7 and 8). Figures 4.6 and 4.7 provide clear evidence that MDM2 and R3 acting 
together are able to catalyse proteasome-mediated degradation of p53, 
whereas the E3s acting alone are not. In addition it provides clear evidence that 
the proteasome immunopurified from mammalian cell lysates as part of this 
work is indeed active. 
 
Given the degree of variability of the ubiquitination seen in these assays, an 
objection (albeit an unlikely one) that could be raised is that the ubiquitination 
reaction failed to work exactly in those lanes to which MG132 was added. To 
counter this objection it would indeed have been better to have performed the 
ubiquitination reaction and then split it into 2, adding proteasome to one half but 
not to the other. That would have ensured that the same amount of 
ubiquitination was present in the reaction to which proteasome was added and 
to which it was not added. This procedure has since been adopted in our 
laboratory for all similar assays involving purified proteasome. 
 
4.6. The DWNN domain is not required for ubiquitination of p53 
The ubiquitin-like structure of the DWNN domain has previously led us to 
propose that it plays some role in the ubiquitination activity of RBBP6 (Pugh et 
al., 2006). Such a role would not necessarily promote ubiquitination; it could 
also be inhibitory, such as that recently reported for the N-terminal ubiquitin-like 
domain of Parkin (Chaugule et al., 2011). To investigate whether the DWNN 
domain is required for ubiquitination of p53, a truncated form of R3 containing 
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only the zinc knuckle and the RING finger (and hence the named “R2”) was 
amplified from R3 and cloned into a pGEX-6P-2 expression vector by a co-
worker, Ms A’tieyah Salie. The final construct was codon optimised for 
expression in bacteria (inherited from the R3 construct) and contained a C-
terminal His6 tag in addition to the N-terminal GST-tag. 
 
Bioinformatic analysis of the sequence of RBBP6 suggests that the region 
between the DWNN domain and the zinc knuckle is unstructured and plays the 
role of a flexible linker (unpublished observation). As reported above, R3 was 
found to be highly susceptible to degradation in vitro, leading to the hypothesis 
that it may be subject to proteolytic cleavage in this region. If that were the case 
then excluding the flexible region may yield a construct that was more stable 
and therefore more suitable for future structural studies. R2 was therefore 
designed to begin immediately after the linker region of R3, yielding a fragment 
corresponding to residues 143-335 of RBBP6. Including the N-terminal GPLGS 
stemming from the vector and the C-terminal His6 tag, the resulting protein had 
a molecular weight of 22.7 kDa. 
 
GST-R2-His6 was expressed in bacteria by a co-worker, Ms A’tieyah Salie and 
the GST affinity tag removed prior to use in in vitro ubiquitnation assays. The 
quadruple mutant form of p53, p53-QM, served as substrate and was detected 
using the same rabbit polyclonal anti-p53 antibody used in earlier assays (sc-
6243 Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). As mentioned 
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earlier, this antibody produces an artifactual band at 100 kDa and can therefore 
be ignored. 
 
The results are shown in Figure 4.8. Despite high background and evidence of 
uneven transfer of proteins from the gel to the membrane (two whitish sloping 
lines over lanes 1-4), there is nevertheless evidence of poly-ubiquitination of 
p53-QM by GST-R3 and GST-MDM2, acting either separately or together 
(lanes 3-5). This is in line with previous data shown in Figure 4.7. Lane 6 shows 
that R2 (note, no GST) on its own is able to produce poly-ubiquitination of p53-
QM that is at least as significant as that produced by GST-R3 (lane 4). The 
pattern of ubiquitnation produced by MDM2 acting with R2 (lane 7) is similar to 
that produced by MDM2 acting with MDMX (lane 8), and is more significant than 
that produced by GST-MDM2 alone (lane 3). It is possible that the strength of 
the signal at the top of lane 6 has been reduced due to poor blotting efficiency; 
if so the effect produced by R2 alone may in fact be more significant than that 
produced by GST-R3. It should be noted that the lanes 6 and 7 include E2s 
UbcH1 and UbcH5b in addition to the UbcH5a used in lanes 3-5. 
 
Since the ubiquitination activity of R2 appears to be at least as high as that of 
R3, we conclude that the DWNN domain does not enhance the poly-
ubiquitination acitivity of RBBP6 for p53. On the other hand, despite repeated 
attempts we did not find strong evidence that the ubiquitination activity of R2 is 
significantly greater than that of R3, from which we conclude that the DWNN 
domain does not appear to inhibit the activity of RBBP6 for p53. However the 
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greater susceptibility of R3 to proteolysis makes it possible that the “R3” 
samples used earlier in this work were in fact R2. This question will be the focus 
of careful investigation in future work. It can nevertheless be concluded that the 
R2 fragment is more stable than R3 and therefore represents a more promising 
choice for studies of the ubiquitination activity of RBBP6 against p53. 
 
 
Figure 4.8 The DWNN domain is not required for the ubiquitination of p53. The 
ubiquitination of the p53 quadruple mutant (p53-QM) using GST-MDM2, GST-R3, and R2. All 
lanes contain p53-QM and the ubiquitination buffer. Lanes 1 and 2 are no ubiquitin controls, 
with lane 2 containing both E3s as well. Lanes 3-8 all contain ubiquitin. Lane 3 contains GST-
MDM2 and Lane 4 contains GST-R3 with lane 5 containing both GST-MDM2 and GST-R3. 
Lane 6 contains R2 with additional E2s UbcH1 and UbcH5b. Lane 7 is the same as lane 6 with 
additional GST-MDM2. Lane 8 is a control lane containing GST-MDM2 and MDMX with 
additional E2s UbcH1 and UbcH5b. Note that the band at 100 kDa is an artefact of the anti-p53 
antibody which can therefore be ignored. 
 
 
4.7. Poly-ubiquitination of p53 catalysed by RBBP6 is Lys-48 linked  
If all of the intra-chain isopeptide bonds making up a poly-ubiquitin chain involve 
lysine 48 of ubiquitin, then the chain is described as being “lysine48-linked”. 
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Lysine48-linked chains are strongly associated with recognition and degradation 
by the proteasome, although other linkages have recently also been linked with 
proteasomal degradation (Saeki et al., 2009). Hence our earlier conclusion that 
a combination of MDM2 and R3 is sufficient to produce degradation of p53 in 
the presence of the proteasome makes it likely, but not certain, that the 
resulting poly-ubiquitin chains are lysine48-linked. Hence a more reliable 
method is required to establish whether the chains are lysine48-linked. Ubiquitin 
mutants lacking lysine48 cannot form such chains and have therefore been 
used to determine whether particular poly-ubiquitin chains are lysine48-linked or 
not. Expression constructs encoding ubiquitin mutants K48R, with lysine48 
replaced by arginine, and K(0), with all lysines replaced by arginines, were 
expressed in bacteria and purified using the same cation exchange method 
used for wild type ubiquitin, as described in Section 3.7. 
 
Using His6-p53 as the substrate and UbcH5a as E2, fully in vitro assays were 
conducted to establish whether GST-R3, GST-MDM2 and MDMX could 
produce ubiquitination using the different forms of ubiquitin. The results are as 
shown in Figure 4.9. As expected GST-MDM2/MDMX produced clear evidence 
of poly-ubiquitination with wild type ubiquitin (lane 6) but not with ubiquitin-K0 
(lane 7) or ubiquitin-K48R (lane 8), nor when ubiquitin was omitted altogether 
(lane 5), indicating that the poly-ubiquitin chains are lysine48-linked. Similarly, 
GST-MDM2/GST-R3 was able to produce poly-ubiquitination using wild-type 
ubiquitin (lane 2) but not with ubiquitin-K0 (lane 3) or ubiquitin-K48R (lane 4), 
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nor when ubiquitin was omitted altogether (lane 1), confirming that the poly-
ubiquitin chains produced by GST-MDM2/GST-R3 are lysine48-linked. 
 
Other feint bands can be seen between 50 and 100 kDa and above 150 kDa 
which are present in most lanes, including the no-ubiquitin lanes 1 and 5. 
Rather than being evidence of mono-ubiquitination these are more likely to be 
background similar to the artifactual band at 100 kDa seen in earlier assays.  
 
An important draw-back of the results shown in Figure 4.9 are that there are no 
positive controls for the ubiquitin mutants, to show that they were present in 
similar quantities to wild type ubiquitin and competent to produce ubiquitination 
under the right circumstances. Ideally the Western blot should have been 
stripped and re-probed with anti-ubiquitin antibodies in order to show that 
simillar quantities of all three were present in the assays. Alternatively, using 
anti-ubiquitin to detect ubiquitinated p53 would also have allowed the amount of 
ubiquitin present to be gauged. More sophisticated controls would include the 
use of substrates known to be poly-ubiquitinated with chain-linkages other than 
lysine48, in order to verify that ubiquitin-K48R is competent to produce such 
chains. However, the preliminary nature of the result in Figure 4.9 did not justify 
the use of such complex controls. 
 
In addition, in light of the earlier discussion of the possible effects of GST on the 
ubiquitination activity of MDM2, Figure 4.9 does not rule out the possibility that 
the poly-ubiquitination in lanes 2 and 6 is due to GST-MDM2 alone, in which 
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case no conclusions could be drawn about the linkages of chains catalysed only 
by the combination of MDM2 and R3.  For this reason it would have been useful 
to have included E3s without GST attached. Unfortunately time constraints did 
not allow this, but it is the focus of ongoing reseach in the laboratory. 
 
Figure 4.9. Poly-ubiquitination of p53 by GST-MDM2/GST-R3 is lysine48-linked. Poly-
ubiquitination by GST-MDM2/GST-R3 is apparent when wild type ubiquitin is used (lane 2) but 
not when the K48R (lane 3) or K0 (lane 4) mutants are used, nor when ubiquitin is omitted 
entirely (lane 1). Similar results are observed for GST-MDM2/MDMX, which is as expected and 
therefore lends credibility to the results for GST-MDM2/GST-R3. 
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4.8. RBBP6 could potentially serve as an E4 poly-ubiquitin chain extension 
factor for p53 
An E4 chain extension factor is an enzyme that catalyses the extension of an 
existing poly-ubiquitin chain, but not the addition of the first ubiquitin to the 
substrate. Due to the fact that RBBP6 has been reported to facilitate poly-
ubiquitination of p53 by MDM2, but not to be able to catalyse ubiquitination 
itself, the question should be asked whether RBBP6 plays the role of an E4 for 
p53. Wu and co-workers showed that Ube4b is an E4 for p53 using a 2-step 
assay in which MDM2 was first used to mono-ubiquitinate p53, whereafter p53 
was immunoprecipitated and then added to a fresh ubiquitination reaction 
including Ube4b but not MDM2 (Wu et al., 2011). The results of an initial 
investigation using the above protocol are shown in Figure 4.10(A). The assay 
was conducted using p53, MDM2 and R3, with all GST tags removed.  
 
High molecular weight bands are seen when MDM2 was added in Step 1 
(before immunoprecipitation) and R3 in Step 2 (after immunoprecipitation) (lane 
5) but not when R3 was omitted from Step 2 (lane 4), which suggests that R3 is 
required for poly-ubiquitination of p53. But similar bands are not seen when 
MDM2 was omitted from Step 1 (lane 3), which suggests that R3 cannot poly-
ubiquitnate without prior mono-ubiquitination by MDM2. As expected, poly-
ubiquitination was also not seen when R3 was added to Step 1 and MDM2 to 
Step 2 (lane 6), nor when both E3s were omitted from both steps (lanes 1 and 
2). The heavy signal between 25 and 50 kDa is largely due to detection by the 
secondary antibody of the heavy and light chains of the anti-p53 primary 
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antibody, which was present on the membrane because of its presence in the 
SDS-PAGE due to its use in the immunoprecipitation step. 
 
The result shown in panel (A) suggests that R3 is only able to poly-ubiquitinate 
p53 following prior mono-ubiquitination by MDM2. It also implies that MDM2 and 
R3 do not have to be present simultaneously at the substrate in order to poly-
ubiquitinate it, which contrasts with a model in which MDM2 and R3 have to 
associate directly during ubiquitination, such as in the scaffold model proposed 
by Li and co-workers (Li et al., 2007). However, despite numerous attempts to 
repeat this result, such as the assay shown in panel (B), no further evidence of 
poly-ubiquitination in a 2-step assay was found. Hence the question of whether 
R3 and MDM2 work sequentially or simultaneously or, in other words whether 
R3 functions as an E4 ligase, remains to be resolved. 
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Figure 4.10 “Two-step” assay to determine if R3 functions as an E4. (A) and (B) Step I is 
MDM2 mono-ubiquitination. p53 is then immunoprecipitated using anti-p53 and step II is the R3 
poly-ubiquitinating step using the mono-ubiquitinated p53 from step I. p53, MDM2 and R3 have 
been cleaved and purified of their GST tags. Lane 1 and 2 are the controls containing no E3s. 
Lane 3 has nothing added in step I, but R3 is added in step II. Lane 4 has MDM2 only added in 
step I and nothing in step II. Lane 5 has MDM2 added in step I and R3 added in step II. Lane 6 
has R3 added in step I and MDM2 added in step II. The immunoprecipitation was done with 
anti-p53 rabbit polyclonal antibody and Western blotted using 1:1000 anti-p53 rabbit polyclonal 
antibody; secondary 1:2000 donkey anti-rabbit antibody. 
 
 
4.9. p53 and R3 interact directly in vitro 
Simons and co-workers have previously reported that RBBP6 interacts directly 
with p53, and identified a “p53 binding region” near the C-terminus of RBBP6 
(Simons et al., 1997). Our results suggest that the R2 and R3 fragments of 
RBBP6, which do not contain the domain identified by Simons and co-workers 
is nevertheless able to ubiquitinate p53 raising the question of whether the R3 
fragment can bind directly to p53. A Far Western blot, or “blot overlay”, was 
performed to test this possibility. In a Far Western blot, a PVDF membrane onto 
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which one of the putative interactors (call it Protein 1) has been blotted, is 
incubated with the other interactor (call it Protein 2) and then washed to remove 
non-interacting Protein 2. The membrane is then immunodetected using 
antibodies recognising Protein 2. If the two proteins interact then Protein 2 will 
be detected at molecular weights characteristic of Protein 1. An advantage of 
the method is that the interactions of a single Protein 2 can be investigated 
simultaneously with a number of different Protein 1s (R. Hall, 2004).  
 
The results can be seen in Figure 4.11(A). In this case, Protein 2 was p53 and 
the set of Protein 1s contained GST-R3 (lane 6; approximately 60 kDa), as well 
as proteins expected to interact with p53 including GST-MDM2 (lane 1; full 
length at 100 kDa and major degradation product at 60 kDa) and the E2 
UbcH5c (lane 2; 17 kDa), as well as GST (lane 3; 27 kDa), which is not 
expected to interact with p53. The above proteins were separated by SDS 
PAGE, transferred to a PVDF membrane and incubated with p53, after which 
the membrane was washed thoroughly to remove unbound p53. The membrane 
was then immunodetected with rabbit poly-clonal anti-p53 antibody (sc-6243 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Figure 4.11(B) is an 
independent repeat of (A) with proteins loaded as indicated.  
 
The detection of p53 in lane 2 at the molecular weight of UbcH5c and the lack 
of p53 at the molecular weight of GST in lane 3 generate confidence that the 
assay is working as expected. In addition, the ladder of bands in lane 1 in both 
(A) and (B) suggests that p53 interacts with MDM2 and its degradation 
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products, again as expected. The ladder of bands in lane 4 in (A) and lane 3 in 
(B), at molecular weights consistent with GST-R3 and its degradation products 
suggests that there is a direct interaction between R3 and p53.  
 
 
 
Figure 4.11 Far Western blot overlay showing interaction between p53 and GST-R3. GST-
R3 interact directly with p53 ((A) lane 4 and (B) lane 3) M is the marker lane. (A) Lanes 1 and 2 
contain the positive controls GST-MDM2 and UbcH5c respectively. Lane 3 the negative control 
GST. Lane 4 contains GST-R3. (B) Lane 1 is the positive control GST-MDM2. Lane 2 is the 
negative control GST and lane 3 is GST-R3. Equal amounts of each protein were loaded onto 
the gel and separated. Transfer onto PVDF membrane, blocking and subsequent probing using 
100 ng of His-p53 protein. A 1:750 dilution of anti-p53 rabbit polyclonal antibody and 1:1000 
dilution of donkey anti-rabbit secondary antibody used. 
 
(A) 
(B) 
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CHAPTER 5 
Discussion and Conclusion 
 
It has been previously established by Li and co-workers that Retinoblastoma 
Binding Protein 6 (RBBP6) plays a major role in suppressing levels of p53 
levels during development by promoting its poly-ubiquitination and degradation 
in the proteasome (Li et al., 2007). The main objective of this project was 
therefore to investigate the role of RBBP6 in ubiquitination of p53 in more detail 
using in vitro assays. Since RBBP6 is a large, multi-domain protein that is 
unsuited to expression in bacteria, a shortened fragment dubbed R3 and 
containing the first three domains of RBBP6 (DWNN, zinc knuckle and RING 
finger domains), was used in vitro assays. The fact that this fragment 
corresponds to the major isoform of RBBP6 found in lower eukaryotes lends 
support to the hypothesis that R3 contains most, if not all, of the ubiquitination 
activity of full length RBBP6. However, since it excludes the reported p53 
binding domain near the C-terminus of RBBP6, if it were able to catalyse 
ubiquitination of p53 it would potentially rule out the model proposed by Li and 
co-workers whereby RBBP6 functions as a scaffold bringing p53 and MDM2 
together. 
 
In vitro ubiquitination reactions required the bacterial expression and purification 
of a number of different proteins, including the substrate p53 (wild type, both 
His6- and GST-tagged and the stabilised quadruple mutant which was His6-
tagged), ubiquitin-ligating enzymes R3 and MDM2, E1, a number of different 
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ubiquitin conjugating enzymes (E2s), ubiquitin activating enzyme (E1) and 
ubiquitin (wild-type and mutants K0 and K48R). The 26S proteasome was 
immunopurified from human cell lysates supplied by a co-worker. 
 
As a first step, “partially in vitro” assays were conducted using human cell lysate 
to supply E1 and E2 enzymes, as well as the proteasome. The proteasome 
inhibitor MG132 and the poly-ubiquitin-binding protein MultiDsk were added to 
block the action of the proteasome and de-ubiquitination enzymes respectively. 
Addition of both R3 and MDM2 to HepG2 lysate led to massive increase of 
higher molecular weight species of p53 consistent with poly-ubiquitination 
(Figure 4.1, panel A). However there was no consistent decrease indicative of 
proteasome-induced degradation when MG132 was omitted. This could be due 
to the proteasome not being active or to the poly-ubiquitination not targeting p53 
to the proteasome. When the assay was repeated the same heavy poly-
ubiquitination was observed, but only when both R3 and MDM2 were present 
(panel B). Addition of MultiDsk again had no significant effect; whether this was 
due to lack of active proteasome or de-ubiquitination enzymes, or to insufficient 
or non-functional MultiDsk is difficult to determine from this preliminary 
summary.  
 
Although this assay provides no evidence about the mechanism behind the 
effect, it nevertheless shows conclusively that R3 stimulates poly-ubiquitination 
of p53. Since roughly equal amounts of R3 and MDM2 were used in the assay 
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(data not shown), it suggests that the activity of R3 is of the same order as that 
of MDM2, which is known to be the most important regulator of p53. 
 
The first fully in vitro assays were conducted using the MDM2/MDMX system as 
a bench-mark as it is well known to produce poly-ubiquitination of p53. A simple 
titration assay was conducted using a small selection of E2s (UbcH1, UbcH5a, 
UbcH5b and UbcH5c) in which concentrations of GST-MDM2/MDMX were 
progressively increased in order to determine which concentration gave the best 
ubiquitination of p53. This was repeated for GST-MDM2/GST-R3 and although 
the results were not as impressive as that of the MDM2/MDMX combination, it 
established that we were able to produce ubiquitination of p53 in a fully in vitro 
assay using approximately 1 µM of GST-MDM2 and GST-R3. However it should 
be admitted that the lack of a no-MDM2 control means that the possibly that the 
effect is entirely due to MDM2 is not ruled out. 
 
Ubiquitin conjugating enzymes (E2s) UbcH5a and UbcH5c were found to work 
best with GST-MDM2 and GST-R3 in ubiquitinating p53. As previously, the lack 
of a no-MDM2 control means that this assay does not rule out the possibility 
that the effect is entirely due to GST-MDM2 which has been reported to be able 
to catalyse poly-ubiquitination. Nevertheless, this result prompted us to use 
UbcH5a and UbcH5c as first choice E2s in subsequent investigations. In order 
to address the problems raised in the previous two assays, R3 and MDM2 were 
added separately and in combination in the next in vitro reaction. GST was also 
removed from GST-R3 in order to avoid potential artefacts resulting from GST-
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driven dimerisation. Figure 4.5 shows that un-tagged R3 was able to at least 
mono-ubiquitinate p53 in vitro (lane 3), producing an effect similar to that of 
GST-MDM2. When R3 and GST-MDM2 were combined the effect was stronger, 
although whether this qualifies as cooperative behaviour or is simply additive is 
not clear from this assay. Although from this assay we could establish that GST-
R3 independently plays a role in the ubiquitination of p53, the GST attached to 
MDM2 may cast a negative shadow on these promising results. MDM2 was 
found to be able to degrade quickly once expressed and purified, even with the 
GST tag attached (Figure 4.11 B), although the GST did provide a mechanism 
for this process to occur at a slower pace as compared without the GST. Due to 
time limitations, these assays were not repeated with their non-GST 
counterparts. Future work would include cleaving MDM2 and R3 from its GST 
tag and utilising it in assays immediately before the degradation becomes too 
severe.  
 
The previous assay suggested that R3 was at least able to multiply mono-
ubiquitinate p53, and that R3 and MDM2 may show cooperative behaviour. This 
posed the question of whether R3, acting either alone or in combination with 
MDM2, was able to catalyse poly-ubiquitination leading to proteasomal 
degradation. In order to investigate this, intact proteasomes were 
immunopurified from human cell lysates and added to in vitro ubiquitin 
reactions. Figure 4.6(A) shows that although both GST-R3 and GST-MDM2 
were able to catalyse what appears to be poly-ubiquitination, producing a 
number of bands greater than 150 kDa, it did not appear to result in degradation 
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in the proteasome. In contrast, when GST-R3 and GST-MDM2 were used 
together the p53 appeared to be completely degraded. Supporting this 
conclusion, addition of MG132 completely rescued p53 and poly-ubiquitinated 
bands. This result suggests strongly that R3 and MDM2, acting together, are 
able to catalyse poly-ubiquitination that is recognised by the proteasome, 
whereas acting independently they are not. 
 
The above result therefore supports the conclusions of Li and co-workers (Li et 
al., 2007) that RBBP6 cooperates with MDM2 to poly-ubiquitinate p53, leading 
to degradation in the proteasome. However, whereas their result was achieved 
in vivo, where un-identified factors may be present, this result was achieved in 
the defined environment of an in vitro assay. In addition, this result was 
obtained using the smaller R3 fragment of RBBP6 (residues 1  335), which 
does not contain the putative p53-binding domain identified previously (Simons 
et al., 1997). It would therefore appear to rule out the scaffold model proposed 
by Li and co-workers in which RBBP6 brings MDM2 and p53 together. 
 
An objection that can be raised against the result shown in Figure 4.6 is that 
p53, MDM2 and R3 are all tagged with GST. It may be suggested that homo-
dimerisation of GST may influence the results, as shown for GST-MDM2 by 
Wang and co-workers (Wang et al., 2011). However the fact that GST-MDM2 
and GST-R3 were unable to catalyse degradation of p53 under exactly the 
same conditions suggests strongly that GST is not responsible for the effect. 
Nevertheless attempts were therefore made to remove GST from the substrate 
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and both E3s; however this proved extremely difficult as the protein became 
unstable and prone to precipitation, reducing concentrations and introducing 
degradation products which complicated analysis of ubiquitination ladders. This 
was particularly problematic for MDM2, and the concentrations of MDM2 in 
many of our assays were possibly lower than expected due to degradation and 
precipitation. For this reason, it would have been a good idea to strip Western 
blots following detection of p53, re-probing with anti-MDM2 and anti-R3 to 
establish how much of each E3 was present in each assay. However this 
proved technically very challenging and time-consuming and was therefore 
deemed to be outside of the scope of this thesis. 
 
In an attempt to address the instability of p53, a mutant form was cloned and 
expressed in bacteria which incorporated four single amino acid mutations 
reported to stabilise the protein in vitro. Figure 4.7 shows that this form, denoted 
p53-QM for “quadruple mutant”, can also be poly-ubiquitinated by R3 (no GST 
tag). As before, R3 appears to be more effective in poly-ubiquitinating p53 when 
acting in conjunction with GST-MDM2, and this poly-ubiquitinating is able to 
catalyse degradation in the proteasome (compare lanes 9 and 10). 
 
The ubiquitin-like structure of DWNN domain raised the question as to whether 
it plays a role in the ubiquitination activity of R3. To address this question a 
shortened form of R3, excluding the DWNN domain and denoted R2, was 
cloned and expressed by a co-worker and incorporated into in vitro 
ubiquitination assays. 
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The ubiquitination activity of R2 (no GST tag) was not significantly different from 
that of GST-R3 (Figure 4.8). This would appear to rule out the hypothesis that 
the DWNN domain functions as an inhibitory domain similar to that of Parkin 
(Chaugule et al., 2011), but rather suggests that it is not required for the 
ubiquitination of p53. However R2 was found to be more stable than R3 and 
therefore more suitable for future functional and structural studies. Attempts to 
express sufficient quantities of R2 for NMR-based structural analysis are 
ongoing in the laboratory. 
 
In this thesis we have shown unequivocally that R3 and MDM2, acting together, 
are able to catalyse addition of poly-ubiquitin chains to p53. The disappearance 
of both p53 and its ubiquitinated isoforms in the presence of 
immunoprecipitated proteasome, and their re-appearance in the presence of 
MG132, suggest that these chains are lysine48-linked. In order to further 
investigate the mode of linkage, ubiquitin mutants K(0) (all seven lysines 
replaced with arginines) and K48R (lysine48 replaced with arginine) were 
expressed and purified and incorporated in our in vitro ubiquitination assays. As 
shown in figure 4.9, poly-ubiquitination was seen when wild type ubiquitin was 
used, but neither when K(0) nor when K48R was used. This result reinforces 
the conclusion that he poly-ubiquitin chains produced by R3 and MDM2 are 
lysine48-linked. The three forms of ubiquitin behaved similarly during 
expression and purification, yielded similar amounts of protein and the same 
amounts were added to each assay; it would nevertheless have improved the 
assay if the blot shown in Figure 4.9 had been stripped and re-probed with anti-
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ubiquitin to demonstrate that sufficient quantities of the mutants were present. 
This was not attempted for the reason outlined earlier. 
 
A major drawback encountered in this thesis was the large variability of in vitro 
ubiquitination assays. A number of factors contribute to this. The first is the 
complex nature of the ubiquitnation reaction, which consists of not one, but 
three consecutive enzymatic reactions. As with all enzymatic reactions, each is 
highly sensitive to the purity and quantity of reactants, including the presence of 
degradation products and contaminants, among other factors. The result is that 
the overall reaction depends sensitively on a number of unknown factors, 
leading to large variation in the results.   
 
A second factor contributing to variability is the method of detection.  Western 
blots rely on transfer of proteins from a poly-acrylamide gel to a membrane, a 
process which is not always equally efficient for all proteins and often shows 
different efficiency within different parts of the same gel. Western blotting relies 
furthermore on the binding of antibodies to target proteins; antibodies are 
themselves highly unreliable and their efficacy may differ significantly from one 
batch to another. Chemiluminescence, because it is also an enzymatic process, 
is again a highly variable process. It also has poor linearity, which means that 
the strength of the signal is not always well correlated with the quantity of 
protein being detected. In particular they saturate easily, which makes them 
particularly poor at distinguishing between strong signals. 
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Despite all of these drawbacks, Western blotting remains the standard method 
for studying ubiquitination.  Nevertheless, there are a number of improvements 
could be made in future to reduce the variability of our results. One is the 
replacement of chemiluminescent detection with fluorescent detection. Instead 
of using secondaries conjugated to horseradish peroxidase, secondaries 
conjugated to fluorophores are used, with detection using a fluorescnce-
enabled camera. This has been shown to be significantly more linear than 
chmiluminescence. An additional advantage is that it is compatible with 
multiplexing, which means that more than one protein can be detected 
simultaneously. This would have proved useful in quantitating enzymes such as 
the various E2s and E3s which would otherwise have required repeated 
stripping of the blot and re-probing with different antibodies. However this 
requires specialise equipment which was not available in our laboratory during 
the course of this project. 
 
Another possible improvement would involve replacing Western blot detection 
with a plate-based solution assay. An example is the AlphaLisa technology from 
Perkin Elmer, in which the substrate is coupled to a fluorophore and another 
fluorophore is coupled to a protein with high affinity for poly-ubiquitin chains. 
Poly-ubiquitination of the substrate causes the two fluorophores to come into 
close proximity with one another, leading to modulation of their fluorescence 
spectra which is detected by a plate reader. Use of this technology was 
attempted at the very beginning of this project, but it was not found to be easy 
to use and was abandoned in favour of Western blot-based detection. 
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Perhaps the easiest was of improving the assays used here would be to replace 
the p53-specific antibodies, which were repeatedly found to be of poor quality 
and variable from batch to batch, with a reliable antibody targeting an immuno-
tag. Since p53 was heterologously produced in bacteria, it would have been 
very simple to engineer the expression plasmid to include an immuno-tag such 
as HA, cMyc or FLAG. 
 
Another way in which ubiquitination assays could be simplified and therefore 
rendered less variable would be through use of E2 enzymes pre-charged with 
ubiquitin, thereby eliminating both the E1 activation step and the transfer of the 
ubiquitin from the E1 to the E2. UbcH5a, which was found to be active with 
respect to p53 , RBBP6 and MDM2, is commercially available as an ubiquitin 
conjugate (for example Cat E2-802, R&D Systems, Inc., Minneapolis MN, USA). 
Such a system may be useful in situations where the role of UbcH5a had 
already been established; however in other investigations it may also be too 
restrictive and eliminate a number of alternative ubiquitination mechanisms. 
 
RBBP6 was previously found to interact with p53 in a region near to the C-
terminus of RBBP6 (Sakai et al., 1995). The ability of the R3 fragment of 
RBBP6, which does not include the putative p53-binding domain, to catalyse 
ubiquitination of p53, with or without the assistance of MDM2, suggests that 
RBBP6 contains another p53 binding site, located within R3. Far Western blots 
were conducted in order to test this hypothesis, which involved incubating a 
membrane containing R3 and other potential interactors with recombinant p53, 
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followed by immunoblotting with anti-p53 antibody both (Figure 4.11). As shown 
in Figure 4.11, this method confirmed the presence of an interaction between 
GST-MDM2 and GST-R3, both of which are known to interact with p53, but no 
interaction was detected with GST, as expected.  
 
In conclusion, this thesis provided strong support for the hypothesis that 
Retinoblastoma Binding Protein 6 (RBBP6) has ubiquitin ligase activity against 
p53 in vitro, using members of the UbcH5 family of ubiquitin conjugating 
enzymes (E2s). Although the results do not distinguish clearly between poly-
ubiquitination and multiple mono-ubiquitination, there is at least some evidence 
that R3 may be able to catalyse poly-ubiquitination of p53. There is also strong 
evidence that when R3 and MDM2 are used together p53 is poly-ubiquitinated, 
leading to degradation in the proteasome. As expected these poly-ubiquitin 
chains are lysine48-linked, as was shown using the K48R mutants of ubiquitin. 
Assays were carried out using the stabilised quadruple mutant of p53 which 
demonstrated that the mutant is susceptible to ubiquitination and therefore a 
suitable substrate for in vitro investigations of the ubiquitin-mediated regulation 
of p53 (Joergher et al., 2004). 
 
Since R3 does not contain the reported p53-binding site of RBBP6, and the 
DWNN domain is not required for ubiquitination activity, the minimal active 
region of RBBP6 appears to be contained within the smaller R2 fragment. It is 
therefore unlikely that RBBP6 plays the role of a scaffold suggested by Li and 
co-workers (Li et al., 2007), bringing p53 and MDM2 together. What then could 
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be the mechanism whereby R3 influences MDM2 in ubiquitination of p53? A 
possible scenario is that RBBP6 and MDM2 form a hetero-dimer through their 
respective RING finger domains, similar to the hetero-dimer formed between 
MDMX and MDM2. Future structural investigations will concentrate on this 
fascinating possibility.  
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Appendix 
 
(A) Materials and suppliers 
40% 37.5:1 acrylamide: bis-acrylamide   Merck 
Agarose       Separations 
Ammonium persulphate                                        Merck 
Ampicillin                                                                    Sigma 
Antibodies                                                                Santa Cruz  
Biotechnology 
Calcium chloride                                                      Merck 
Casein       Sigma 
Coomassie Blue R-250                               Sigma 
Ethanol                                                   Merck 
Ethylene diamine tetra acetic acid (EDTA)            Merck 
Glacial acetic acid                                           Merck 
Glycerol                                              Merck 
Glycine                                               Merck 
Hydrochloric acid                                              Merck 
 
 
 
 
129 
 
Imidazole                                                Sigma 
Isopropanol  (Propan-2-ol)                                            Merck 
Kanamycin mono-phosphate                                Sigma 
Magnesium chloride                                                 Merck 
Methanol                                                                 Merck 
N, N, N’, N’-Tetra methylethylene-diamine (TEMED)   Sigma 
Nutrient agar                                                           Merck 
Potassium acetate                                                   Merck 
Potassium chloride                                                     Merck 
Protease inhibitor cocktail                                          Roche 
Restriction enzymes                                                  Thermo Scientific 
Sodium chloride                                                         Merck 
Sodium dodecyl sulphate                                             Merck 
T4 ligase                                                                   Thermo Scientific 
Tris [hydroxymethyl] aminomethane                         Merck 
Triton X-100                              Merck 
Tryptone                                                                   Merck 
Yeast extract                                                             Merck 
Glutathione agarose                                                 Sigma 
Nickel sepharose                                                        Sigma  
 
(B)  General Stock solutions and buffer preparation  
Ammonium Persulphate: A 10% stock solution was prepared in deionised 
water. The solution was stored at 4 °C.  
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Ampicillin: A 100 mg/ml stock solution was prepared in deionised water. The 
solution was filter-sterilized using a 0.22 micron filter and stored at -20 °C.  
 
Binding buffer (Proteasome purification): 1 x PBS, 10% Glycerol, 1 mM DTT 
 
Coomassie Staining Solution: 0.25 g Coomassie Blue R-250, 40% ethanol 
and 10% acetic acid in 250 ml deionised water.  
 
Destaining Solution: 40% ethanol (v/v) and 10% acetic acid (v/v) in 250 ml 
deionised water.  
 
DTT: 1M stock prepared and stored at -20 °C. 
 
GTE: 50 mM glucose, 50 mM Tris-HCl and 10 mM EDTA, pH 8.0.  
 
Immunoprecipitation buffer (IP buffer): 1 x PBS, 10% glycerol and 0.5 mM 
ZnSO4 
 
IPTG: A 1 M stock solution was prepared in deionised water. The solution was 
filter-sterilized, aliquoted and stored at -20 °C.  
 
Kanamycin:  A 50 mg/ml stock solution was prepared in deionised water and 
stored at -20 °C.  
 
Luria Agar: 10 g/l tryptone powder, 5 g/l yeast extract, 5 g/l NaCl and 14 g/l 
bacteriological agar.  
 
Luria Broth: 10 g/l tryptone powder, 5 g/l yeast extract, 5 g/l NaCl and 2 g/l 
glucose. 
 
Protein Elution Buffer: 20 mM reduced glutathione, 1x PBS (for GST tagged 
proteins) and 300-400 mM imidazole, 1 x PBS (for His6- tagged proteins).  
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Protein Extraction Buffer: 1x PBS, 100 µg/ml lysozyme, 10 mM β-
mercaptoethanol, 0.5% Triton X-100, 20 μg/ml ZnSO4, CompleteTM EDTA-free 
protease inhibitor cocktail.  
 
Protein Wash Buffer: 1x PBS, 1 mM β-mercaptoethanol.  
 
2x SDS PAGE Sample Buffer: 4% SDS, 0.125 M Tris-HCl pH 6.8, 15% 
glycerol and 1 mg/ml Bromophenol Blue. The buffer was stored at room 
temperature and 100 mM freshly prepared DTT was added immediately prior to 
use.  
 
10x SDS PAGE Electrophoresis Buffer: 30.2 g Tris, 144.1 g glycine and 10 g 
SDS dissolved in 1 L distilled water. The buffer was stored at room temperature 
and diluted 10-fold when needed. 
 
Separating Buffer: 1.5 M Tris-HCl, adjusted to pH 8.8 with HCl. The buffer was 
stored at 4 °C.  
 
Stacking Buffer: 0.5 M Tris-HCl, adjusted to pH 6.8 with HCl. The buffer was 
stored at 4 °C.  
 
1x TAE: 40 mM Tris, 20 mM acetic acid and 1 mM EDTA. 
 
TYM Broth: 20 g/l tryptone powder, 5 g/l yeast extract, 3.5 g/l NaCl and 2 g/l 
MgCl2. 
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(C) Strategy behind cloning DWNN13 into pmEGFP (originally cloned in the 
incorrect orientation in pEGFP) 
 
Clone into XhoI and KpnI sites of pEGFP-C1; note that the 
XhoI site is in frame 2 in pEGFP, so needs an insertion of 
2 bases (in yellow) to complete the frame. Neither of these 
enzymes occurs in the target sequence. 
 
 
GFP-DWNN13-f: 5’- GAGGCG CT CGA GCT TCC TGT GTG CAT TAT AAA 
TTT T -3’ 
 
 
Tm = 7x4 + 17x2 = 28 + 34 = 62 
 
 
GFP-DWNN13-r: 5’- GAGGCG GGTACC TCA TTA TAA AGG TAA AAG CAA 
TGT G -3’ 
 
 
Tm =  7x4 + 18x2 = 28 + 36 = 64  
 
Sequence of amplicon used to clone DWNN13 into pmEGFP 
 
GGTACCGCGGGCCCGGGATCCACCGGATCTAGATAACTGATCATAATCAGCCATACCAC
ATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAAC
ATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAA
TAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTG
TGGTTTGTCCAAACTCATCAATGTATCTTAACGCGTAAATTGTAAGCGTTAATATTTTG
TTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAAT
CGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAG
TTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACC
GTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTC
GAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGAC
GGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCT
AGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAA
TGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTA
TTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGA
TAAATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGAACCAGCTGTGG
AATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCA
AAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAG
GCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACT
CCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACT
AATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGT
AGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATG
AGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGG
TGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCC
GTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGG
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TGCCCTGAATGAACTGCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCG
TTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTG
GGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATC
CATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCG
ACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTC
GATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAG
GCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCT
TGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTG
GGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCT
TGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGC
AGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCG
AAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCC
TTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCA
GCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCTAGGGGGAGGCTAACTGAAACAC
GGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAA
ACGCACGGTGTTGGGTCGTTTGTTCATAAACGCGGGGTTCGGTCCCAGGGCTGGCACTC
TGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGTTTCTTCCTTTTCCC
CACCCCACCCCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAACGTCGGGGCGGCA
GGCCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTAAAACTTCATTT
TTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT
AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCT
TGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACC
AGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCT
TCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCAC
TTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGC
TGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGG
ATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGA
ACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCC
CGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCA
CGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCAC
CTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAA
CGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGT
TCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCATGCAT 
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(D)  Codon-optimised sequence for cloning superstable quadruple mutant of 
p53 from pET15b into pET28a 
 
 
atggaagaaccgcaatctgacccgagtgttgaaccgccgctgagccaggaaaccttctct 
 M  E  E  P  Q  S  D  P  S  V  E  P  P  L  S  Q  E  T  F  S  20 
gatctgtggaaactgctgccggaaaacaacgttctgagtccgctgccgtcccaggcaatg 
 D  L  W  K  L  L  P  E  N  N  V  L  S  P  L  P  S  Q  A  M  40 
gatgacctgatgctgagcccggatgacattgaacaatggttcaccgaagatccgggtccg 
 D  D  L  M  L  S  P  D  D  I  E  Q  W  F  T  E  D  P  G  P  60 
gacgaagctccgcgcatgccggaagcggcaccgccggtcgcaccggctccggcagctccg 
 D  E  A  P  R  M  P  E  A  A  P  P  V  A  P  A  P  A  A  P  80 
acgccggcagcaccggcaccggcaccgtcctggccgctgagctctagtgtgccgagccag 
 T  P  A  A  P  A  P  A  P  S  W  P  L  S  S  S  V  P  S  Q  100 
aaaacctatcaaggctcttacggttttcgtctgggcttcctgcatagcggtacggcgaaa 
 K  T  Y  Q  G  S  Y  G  F  R  L  G  F  L  H  S  G  T  A  K  120 
tcggttacctgcacgtattctccggcactgaataaactgttttgccagctggctaaaacc 
 S  V  T  C  T  Y  S  P  A  L  N  K  L  F  C  Q  L  A  K  T  140 
tgtccggttcaactgtgggtcgatagcaccccgccgccgggtacgcgtgtccgtgcaatg 
 C  P  V  Q  L  W  V  D  S  T  P  P  P  G  T  R  V  R  A  M  160 
gctatttacaaacagtctcaacacatgacggaagtggttcgtcgctgcccgcatcacgaa 
 A  I  Y  K  Q  S  Q  H  M  T  E  V  V  R  R  C  P  H  H  E  180 
cgctgtagcgattctgacggtctggccccgccgcagcacctgatccgcgtggaaggtaac 
 R  C  S  D  S  D  G  L  A  P  P  Q  H  L  I  R  V  E  G  N  200 
ctgcgtgcggaatatctggatgaccgcaatacctttcgtcattcagtcgtggttccgtac 
 L  R  A  E  Y  L  D  D  R  N  T  F  R  H  S  V  V  V  P  Y  220 
gaaccgccggaagtgggctcggattgtaccacgattcactataactacatgtgctattcc 
 E  P  P  E  V  G  S  D  C  T  T  I  H  Y  N  Y  M  C  Y  S  240 
tcatgtatgggcggtatgaaccgtcgcccgatcctgaccattatcacgctggaagattcg 
 S  C  M  G  G  M  N  R  R  P  I  L  T  I  I  T  L  E  D  S  260 
agcggcaacctgctgggtcgcgatagtttcgaagtccgtgtgtgcgcatgtccgggtcgt 
 S  G  N  L  L  G  R  D  S  F  E  V  R  V  C  A  C  P  G  R  280 
gaccgtcgcaccgaagaagaaaacctgcgtaagaaaggcgaaccgcatcacgaactgccg 
 D  R  R  T  E  E  E  N  L  R  K  K  G  E  P  H  H  E  L  P  300 
ccgggtagcaccaaacgtgcactgccgaacaatacgtctagttccccgcagccgaagaaa 
 P  G  S  T  K  R  A  L  P  N  N  T  S  S  S  P  Q  P  K  K  320 
aaaccgctggatggcgaatattttaccctgcaaatccgtggtcgcgaacgttttgaaatg 
 K  P  L  D  G  E  Y  F  T  L  Q  I  R  G  R  E  R  F  E  M  340 
ttccgcgaactgaacgaagcgctggaactgaaagatgcgcaggccggcaaagaaccgggc 
 F  R  E  L  N  E  A  L  E  L  K  D  A  Q  A  G  K  E  P  G  360 
ggtagtcgtgcccattcatcgcacctgaaaagcaagaaaggccagagcacgagccgccat 
 G  S  R  A  H  S  S  H  L  K  S  K  K  G  Q  S  T  S  R  H  380 
aaaaaactgatgttcaaaacggaaggcccggacagcgactga 
 K  K  L  M  F  K  T  E  G  P  D  S  D  - 
 
 
Codons altered to produce the mutations M133L, V203A, N239Y and N268D are indicated in 
green. 
 
 
 
 
